RunUP Biotech Europa · Catalyst da trialRunUP Biotech Europa · Trial catalysts

Biotech Trials & CatalystBiotech Trials & Catalyst

Calendario dei catalyst da trial clinici in arrivo, USA ed Europa insieme: fase, data stimata e link al record ufficiale su ClinicalTrials.gov. Complementare alla pagina delle medicine in revisione EMA (che copre lo stadio successivo, la domanda regolatoria).Calendar of upcoming clinical-trial catalysts, US and Europe together: phase, estimated date and a link to the official ClinicalTrials.gov record. Complementary to the medicines-under-EMA-review page (which covers the next stage, the regulatory filing).

1.106 catalyst su 407 titoli · ordinati per data · aggiornato 19 luglio 2026 · Solo contenuto educativo1,106 catalysts across 407 tickers · sorted by date · updated 19 July 2026 · Educational content only

Come usare la tabellaHow to use the table

Usa la ricerca per filtrare per ticker, societa’, fase o parola chiave. I pulsanti Area filtrano per mercato di quotazione: US (Nasdaq/NYSE) oppure Ex-US (quotate fuori dagli USA). Il flag Area è un’approssimazione basata sul formato del ticker.Use the search to filter by ticker, company, phase or keyword. The Area buttons filter by listing market: US (Nasdaq/NYSE) or Ex-US (listed outside the US). The Area flag is an approximation based on the ticker format.

Le righe EuropaThe Europe rows

Il blocco Europa raccoglie società quotate su una borsa europea (Euronext, Nasdaq nordici, SIX, Francoforte, Borsa Italiana, BME, LSE) con almeno un trial di fase 2 o 3 in stato attivo e sponsor principale l’azienda stessa. Sono escluse le società europee quotate soltanto negli Stati Uniti. La data indicata è il completamento primario stimato dichiarato su ClinicalTrials.gov: non è la data del readout, che arriva successivamente e con ritardo variabile. Il simbolo di borsa è riportato con il codice MIC del mercato; un asterisco segnala i pochi ticker che non è stato possibile validare automaticamente. Alcune righe riportano partner: sono programmi dell’azienda condotti da un partner industriale che figura come sponsor del trial (per esempio VLA15 di Valneva, sponsorizzato da Pfizer, o NANORAY-312 di Nanobiotix, passato a Johnson & Johnson): restano catalyst per il titolo anche se il nome sullo studio è quello del partner.The Europe block gathers companies listed on a European exchange (Euronext, Nordic Nasdaq, SIX, Frankfurt, Borsa Italiana, BME, LSE) with at least one active Phase 2 or 3 trial where the company itself is lead sponsor. European companies listed only in the United States are excluded. The date shown is the estimated primary completion declared on ClinicalTrials.gov: it is not the readout date, which follows later with variable delay. The exchange symbol carries the market MIC code; an asterisk flags the few tickers that could not be validated automatically. Some rows show partner: these are company programs run by an industrial partner listed as trial sponsor (for example Valneva’s VLA15, sponsored by Pfizer, or Nanobiotix’s NANORAY-312, transferred to Johnson & Johnson): they remain catalysts for the stock even though the study carries the partner’s name.

Data (stima)Date (est.)	Area	Ticker	Societa’Company	Catalyst / FaseCatalyst / Phase	Trial (ClinicalTrials.gov)Trial (ClinicalTrials.gov)
2026-07	EU	CAMX XSTO	Camurus	Phase 3	A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
2026-07-31	EU	ORNBV XHEL	Orion Corporation	Phase 1/Phase 2	Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
2026-08	EU	ARGX XBRU	argenx	Phase 2	A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
2026-08-13	EU	ZEAL XCSE	Zealand Pharma	Phase 2	Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
2026-08-17	EU	BIOA-B XSTO	BioArctic	Phase 2	Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy
2026-09	EU	ARGX XBRU	argenx	Phase 3	A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
2026-09-30	EU	ARGX XBRU	argenx	Phase 2/Phase 3	A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
2026-10	EU	PHARM XAMS	Pharming	Phase 2	Leniolisib for Immune Dysregulation in CVID
2026-10	EU	PHIL XMIL	Philogen	Phase 1/Phase 2	Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
2026-10-01	EU	ARGX XBRU	argenx	Phase 3	A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
2026-10-05	EU	SOBI XSTO	Swedish Orphan Biovitrum	Phase 3	A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
2026-11	EU	DBV XPAR	DBV Technologies	Phase 3	Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
2026-11	EU	ARGX XBRU	argenx	Phase 2	A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
2026-11	EU	PHARM XAMS	Pharming	Phase 2	Leniolisib for Immune Dysregulation in PIDs
2026-11-30	EU	PHARM XAMS	Pharming	Phase 3	Pediatric Patients Aged 4 to 11 Years With APDS
2026-11-30	EU	BAVA XCSE	Bavarian Nordic	Phase 2	Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
2026-12	EU	ABVX XPAR	Abivax	Phase 2	Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
2026-12-01	EU	ARGX XBRU	argenx	Phase 2/Phase 3	A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
2026-12-04	EU	VLA XPAR	Valneva	Phase 3 partner: Pfizer	A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
2026-12-30	EU	SOBI XSTO	Swedish Orphan Biovitrum	Phase 2	A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
2026-12-31	EU	NWRN XSWX	Newron Pharmaceuticals	Phase 3	Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
2027-02	EU	ARGX XBRU	argenx	Phase 2	A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
2027-02	EU	GMAB XCSE	Genmab	Phase 3	Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
2027-02	EU	BAVA XCSE	Bavarian Nordic	Phase 2	A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
2027-02	EU	ALM^* XMAD	Almirall	Phase 2	A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
2027-02-28	EU	HNSA XSTO	Hansa Biopharma	Phase 2	Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
2027-03	EU	ARGX XBRU	argenx	Phase 2/Phase 3	Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
2027-03	EU	GMAB XCSE	Genmab	Phase 2	A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
2027-03	EU	SOBI XSTO	Swedish Orphan Biovitrum	Phase 3	Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
2027-03	EU	FARON^* XHEL	Faron Pharmaceuticals	Phase 1/Phase 2	A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
2027-04-25	EU	ALM^* XMAD	Almirall	Phase 3	A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
2027-04-30	EU	ARGX XBRU	argenx	Phase 2	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
2027-05	EU	VICO XSTO	Vicore Pharma	Phase 2	A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
2027-05-25	EU	ALM^* XMAD	Almirall	Phase 2	A Study of LAD191 in Adults With Hidradenitis Suppurativa
2027-06	EU	IPH XPAR	Innate Pharma	Phase 2	IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
2027-06	EU	ALBPS XPAR	Biophytis	Phase 2	Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
2027-06	EU	GMAB XCSE	Genmab	Phase 3	A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2027-06	EU	IDIA XSWX	Idorsia	Phase 2	A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo
2027-06-23	EU	ALM^* XMAD	Almirall	Phase 2	A Study of LAD603 in Adults With Alopecia Areata
2027-07	EU	ALSEN XPAR	Sensorion	Phase 1/Phase 2	A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
2027-07	EU	ARGX XBRU	argenx	Phase 3	A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
2027-07	EU	GMAB XCSE	Genmab	Phase 1/Phase 2	Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
2027-07-30	EU	GMAB XCSE	Genmab	Phase 3	Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
2027-08	EU	GNFT XPAR	Genfit	Phase 2	Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
2027-09	EU	ARGX XBRU	argenx	Phase 3	A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
2027-09	EU	GMAB XCSE	Genmab	Phase 3	An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
2027-09	EU	GMAB XCSE	Genmab	Phase 1/Phase 2	Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
2027-09	EU	NYKD XOSL	Nykode Therapeutics	Phase 1/Phase 2	Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
2027-09-30	EU	IVA XPAR	Inventiva	Phase 3	A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
2027-09-30	EU	GMAB XCSE	Genmab	Phase 1/Phase 2	Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
2027-10	EU	ARGX XBRU	argenx	Phase 2	ADAPT Forward 2 – ISA2 – a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
2027-10	EU	PHARM XAMS	Pharming	Phase 2	Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
2027-10-07	EU	ARGX XBRU	argenx	Phase 3	A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
2027-11	EU	ARGX XBRU	argenx	Phase 2	A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
2027-11-12	EU	ZEAL XCSE	Zealand Pharma	Phase 2 partner: Roche	A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
2027-11-22	EU	GMAB XCSE	Genmab	Phase 2	Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
2027-11-30	EU	FARON^* XHEL	Faron Pharmaceuticals	Phase 2	Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
2027-12	EU	GNFT XPAR	Genfit	Phase 1/Phase 2	Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
2027-12	EU	GMAB XCSE	Genmab	Phase 1/Phase 2	Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
2027-12	EU	PHIL XMIL	Philogen	Phase 3	Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
2027-12-15	EU	OSE XPAR	OSE Immunotherapeutics	Phase 3	Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
2027-12-30	EU	TNG XPAR	Transgene	Phase 1/Phase 2	A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
2027-12-31	EU	ORNBV XHEL	Orion Corporation	Phase 1/Phase 2	A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
2028-01-27	EU	VLA XPAR	Valneva	Phase 3 partner: Pfizer	A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
2028-01-30	EU	BSLN XSWX	Basilea Pharmaceutica	Phase 3	A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
2028-02	EU	BSLN XSWX	Basilea Pharmaceutica	Phase 3	A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
2028-03	EU	ABVX XPAR	Abivax	Phase 2	Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
2028-03	EU	GMAB XCSE	Genmab	Phase 3	A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2028-03	EU	HPHA XFRA	Heidelberg Pharma	Phase 1/Phase 2	Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
2028-03-07	EU	ARGX XBRU	argenx	Phase 2	ADAPT Forward 1 – ISA1 – a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
2028-04	EU	ARGX XBRU	argenx	Phase 2/Phase 3	A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
2028-04	EU	BAVA XCSE	Bavarian Nordic	Phase 3	Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
2028-05-10	EU	ORNBV XHEL	Orion Corporation	Phase 3 partner: MSD	A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
2028-06	EU	ARGX XBRU	argenx	Phase 3	A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
2028-06	EU	ARGX XBRU	argenx	Phase 3	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
2028-06	EU	ARGX XBRU	argenx	Phase 3	A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
2028-06-30	EU	NANO XPAR	Nanobiotix	Phase 3 partner: Johnson & Johnson	JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
2028-07	EU	PHIL XMIL	Philogen	Phase 2	Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
2028-07-09	EU	PHARM XAMS	Pharming	Phase 3	Pediatric Patients Aged 1 to 6 Years With APDS
2028-08	EU	ALM^* XMAD	Almirall	Phase 3	A Study of Lebrikizumab in Adults With Nummular Eczema
2028-08-02	EU	ORNBV XHEL	Orion Corporation	Phase 3 partner: MSD	Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
2028-09	EU	ARGX XBRU	argenx	Phase 3	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
2028-09	EU	GMAB XCSE	Genmab	Phase 2	Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
2028-09	EU	MOLN XSWX	Molecular Partners	Phase 1/Phase 2	Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
2028-09-18	EU	PHARM XAMS	Pharming	Phase 2	Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
2028-09-18	EU	ZEAL XCSE	Zealand Pharma	Phase 3	Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
2028-10	EU	ARGX XBRU	argenx	Phase 2/Phase 3	A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
2028-10	EU	GMAB XCSE	Genmab	Phase 3	Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
2028-10-23	EU	ZEAL XCSE	Zealand Pharma	Phase 3	Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
2028-12	EU	BAVA XCSE	Bavarian Nordic	Phase 3	A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
2029-01	EU	GMAB XCSE	Genmab	Phase 1/Phase 2	First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
2029-01-15	EU	ORNBV XHEL	Orion Corporation	Phase 1/Phase 2 partner: MSD	Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
2029-01-30	EU	PHIL XMIL	Philogen	Phase 2	A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
2029-03-31	EU	PHARM XAMS	Pharming	Phase 2	Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease
2029-04-02	EU	PHM^* XMAD	PharmaMar	Phase 1/Phase 2	Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
2029-05-28	EU	ARGX XBRU	argenx	Phase 2	A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
2029-06	EU	PRTC XLON	PureTech	Phase 3	Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
2029-07	EU	GMAB XCSE	Genmab	Phase 3	Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer
2029-08	EU	GMAB XCSE	Genmab	Phase 3	Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
2029-08	EU	IDIA XSWX	Idorsia	Phase 3	A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
2029-08-30	EU	PHM^* XMAD	PharmaMar	Phase 3	Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
2029-09	EU	ARGX XBRU	argenx	Phase 2/Phase 3	Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
2029-09	EU	ORNBV XHEL	Orion Corporation	Phase 1/Phase 2	A 2-part Phase 1/2 Open-label Trial on ODM-212
2029-09-30	EU	ARGX XBRU	argenx	Phase 2	A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
2029-12	EU	OSE XPAR	OSE Immunotherapeutics	Phase 1/Phase 2	Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
2029-12	EU	GMAB XCSE	Genmab	Phase 3	Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
2029-12	EU	GMAB XCSE	Genmab	Phase 3	Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
2030-04-30	EU	HNSA XSTO	Hansa Biopharma	Phase 3	A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group
2030-05	EU	BAVA XCSE	Bavarian Nordic	Phase 3	An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
2030-12	EU	GMAB XCSE	Genmab	Phase 1/Phase 2 partner: BioNTech	A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
2030-12-04	EU	ARGX XBRU	argenx	Phase 2	A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults
2031-02	EU	PHIL XMIL	Philogen	Phase 2	L19IL2/TNF in Patients With Basal Cell Carcinoma
2031-02	EU	PHIL XMIL	Philogen	Phase 2	L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
2031-02	EU	PHIL XMIL	Philogen	Phase 2	L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
2032-11	EU	GMAB XCSE	Genmab	Phase 2	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
2037-11	EU	GMAB XCSE	Genmab	Phase 3	Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
2026-07-21	Ex-US	CHIZF	China Traditional Chinese Medicine Holdings Co. Limited	Phase 2	CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
2026-07-26	US	MNKD	MannKind	PDUFA
2026-07-30	US	CERS	Cerus Corporation	Phase 2	A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
2026-07-30	US	QNRX	Quoin Pharmaceuticals, Ltd.	Phase 3	Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
2026-07-31	US	CERS	Cerus Corporation	Phase 3	INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
2026-07-31	US	OCGN	Ocugen, Inc.	Phase 1	Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
2026-08-01	Ex-US	ABSCF	AB Science S.A.	Phase 2	AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
2026-08-01	US	ACIU	AC Immune SA	Phase 1	A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants
2026-08-01	US	ACRS	Aclaris Therapeutics, Inc.	Phase 2	ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
2026-08-01	US	AKBA	Akebia Therapeutics, Inc.	Phase 3	To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
2026-08-01	US	ANRO	Alto Neuroscience, Inc.	Phase 2	ALTO-100 in Bipolar Disorder With Depression (BD-D)
2026-08-01	Ex-US	ASCLF	Ascletis Pharma Inc.	Phase 2	A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
2026-08-01	US	BHVN	Biohaven Ltd.	Phase 1	A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
2026-08-01	US	CADL	Candel Therapeutics, Inc.	Phase 2	A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
2026-08-01	Ex-US	CASBF	CanSino Biologics Inc.	Phase 1	A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years
2026-08-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
2026-08-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
2026-08-01	US	CPHI	China Pharma Holdings, Inc.	Phase 2	A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
2026-08-01	US	CRIS	Curis, Inc.	Phase 2	CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
2026-08-01	US	ENSC	Ensysce Biosciences, Inc.	Phase 3	PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
2026-08-01	US	EYPT	EyePoint, Inc.	Phase 3	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
2026-08-01	US	GPCR	Structure Therapeutics Inc.	Phase 2	Aleniglipron Phase 2 Body Composition Study
2026-08-01	US	HELP	Cybin Inc.	Phase 3	A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
2026-08-01	US	IGC	IGC Pharma, Inc.	Phase 2	Clinical Trial on Agitation in Alzheimer's Dementia
2026-08-01	US	IVVD	Invivyd, Inc.	Phase 3	Study of VYD2311 for the Prevention of COVID-19
2026-08-01	US	IVVD	Invivyd, Inc.	Phase 3	Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
2026-08-01	Ex-US	JBPHF	Jacobio Pharmaceuticals Group Co., Ltd.	Phase 2	JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
2026-08-01	US	KOD	Kodiak Sciences Inc.	Phase 3	A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) – DAYBREAK
2026-08-01	US	KPTI	Karyopharm Therapeutics Inc.	Phase 3	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
2026-08-01	US	KURA	Kura Oncology, Inc.	Phase 1	Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
2026-08-01	US	KYTX	Kyverna Therapeutics, Inc.	Phase 2	KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
2026-08-01	US	MIRM	Mirum Pharmaceuticals, Inc.	Phase 3	A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
2026-08-01	US	MPLT	MapLight Therapeutics, Inc.	Phase 2	A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
2026-08-01	Ex-US	MRCHF	H.U. Group Holdings, Inc.	Phase 3	Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial
2026-08-01	US	NCNA	NuCana plc	Phase 2	A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
2026-08-01	US	PHVS	Pharvaris N.V.	Phase 3	Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
2026-08-01	US	RCUS	Arcus Biosciences, Inc.	Phase 2	Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
2026-08-01	US	RGNX	REGENXBIO Inc.	Phase 2	RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
2026-08-01	US	RGNX	REGENXBIO Inc.	Phase 3	AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
2026-08-01	US	RGNX	REGENXBIO Inc.	Phase 2	RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
2026-08-01	US	RIGL	Rigel Pharmaceuticals, Inc.	Phase 2	Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
2026-08-01	US	RNA	Avidity Biosciences, Inc.	Phase 3	Global Study of Del-desiran for the Treatment of DM1
2026-08-01	US	SLGL	Sol-Gel Technologies Ltd.	Phase 3	Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
2026-08-01	US	VCNX	Vaccinex, Inc.	Phase 1 – Suspended	Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
2026-08-01	US	XENE	Xenon Pharmaceuticals Inc.	Phase 3	A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
2026-08-02	US	REPL	Replimune, Inc.	PDUFA – CRL
2026-08-06	US	MBIO	Mustang Bio, Inc.	Phase 1	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
2026-08-12	US	ACRV	Acrivon Therapeutics, Inc.	Phase 1	Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
2026-08-13	US	JSPR	Jasper Therapeutics, Inc.	Phase 2	A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
2026-08-13	US	LNTH	Lantheus Holdings, Inc.	PDUFA
2026-08-13	Ex-US	ZLDPF	Zealand Pharma A/S	Phase 2	Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
2026-08-15	US	PMVP	PMV Pharmaceuticals, Inc.	Phase 2	The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
2026-08-19	US	SYRE	Spyre Therapeutics, Inc.	Phase 1	A Study of SPY002-091 in Healthy Volunteers
2026-08-24	US	SGMO	Sangamo Therapeutics, Inc.	Phase 1	Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
2026-08-25	US	CLRB	Cellectar Biosciences, Inc.	Phase 1	Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
2026-08-30	Ex-US	MSCLF	Satellos Bioscience Inc.	Phase 2	An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101
2026-08-31	US	IMMP	Immutep Limited	Phase 1	A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers
2026-08-31	US	NRIX	Nurix Therapeutics, Inc.	Phase 1	A Study of NX-1607 in Adults With Advanced Malignancies
2026-08-31	Ex-US	SNPHY	Santen Pharmaceutical Co., Ltd.	Phase 3	A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
2026-08-31	US	VSTM	Verastem, Inc.	Phase 2	Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
2026-09-01	US	ARDX	Ardelyx, Inc.	Phase 3	Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
2026-09-01	US	ARQT	Arcutis Biotherapeutics, Inc.	Phase 2	A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
2026-09-01	US	ARQT	Arcutis Biotherapeutics, Inc.	Phase 2	A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
2026-09-01	US	ARVN	Arvinas, Inc.	Phase 2	TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
2026-09-01	US	ATXS	Astria Therapeutics, Inc.	Phase 1	A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
2026-09-01	US	AVIR	Atea Pharmaceuticals, Inc.	Phase 3	C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
2026-09-01	US	BHVN	Biohaven Ltd.	Phase 2	Taldefgrobep Alfa in Adults With Overweight and Obesity
2026-09-01	US	CGEM	Cullinan Therapeutics, Inc.	Phase 1	A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
2026-09-01	Ex-US	CLRPF	Clarity Pharmaceuticals Ltd	Phase 2	64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
2026-09-01	Ex-US	CLRPF	Clarity Pharmaceuticals Ltd	Phase 3	Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
2026-09-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
2026-09-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
2026-09-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
2026-09-01	US	CRVO	CervoMed Inc.	Phase 2	Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
2026-09-01	US	DSGN	Design Therapeutics, Inc.	Phase 2	DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
2026-09-01	US	EWTX	Edgewise Therapeutics, Inc.	Phase 2	Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
2026-09-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 1	KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
2026-09-01	US	IRON	Disc Medicine, Inc.	Phase 2	Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
2026-09-01	US	IRON	Disc Medicine, Inc.	Phase 3	Study of Bitopertin in Participants With EPP or XLP (APOLLO)
2026-09-01	US	KPTI	Karyopharm Therapeutics Inc.	Phase 2	A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
2026-09-01	US	LEGN	Legend Biotech Corporation	Phase 1	A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
2026-09-01	US	LXRX	Lexicon Pharmaceuticals, Inc.	Phase 1	Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
2026-09-01	US	MAZE	Maze Therapeutics, Inc.	Phase 2	A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
2026-09-01	US	NAMS	NewAmsterdam Pharma Company N.V.	Phase 2	Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
2026-09-01	US	NVCR	NovoCure Limited	Phase 2	Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
2026-09-01	US	ORIC	ORIC Pharmaceuticals, Inc.	Phase 2	Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
2026-09-01	US	PCSA	Processa Pharmaceuticals, Inc.	Phase 2	A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
2026-09-01	US	RAPP	Rapport Therapeutics, Inc.	Phase 2	Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
2026-09-01	US	SLN	Silence Therapeutics plc	Phase 2	Study to Assess SLN124 in Patients With Polycythemia Vera
2026-09-01	US	SNDX	Syndax Pharmaceuticals, Inc.	Phase 2	MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
2026-09-01	US	SUPN	Supernus Pharmaceuticals, Inc.	Phase 3	Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
2026-09-01	US	TYRA	Tyra Biosciences, Inc.	Phase 1	Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
2026-09-01	US	VERA	Vera Therapeutics, Inc.	Phase 2	Monthly Dosing of Atacicept in IgAN
2026-09-01	US	VERA	Vera Therapeutics, Inc.	Phase 2	Monthly Dosing of Atacicept in IgAN
2026-09-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 2	Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
2026-09-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 2	An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
2026-09-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 2	Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
2026-09-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 2	An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
2026-09-01	US	VTVT	vTv Therapeutics Inc.	Phase 3	Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
2026-09-01	US	WVE	Wave Life Sciences Ltd.	Phase 2	A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
2026-09-04	Ex-US	SHEZF	Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	Phase 1	A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
2026-09-11	Ex-US	NPPNY	Nippon Shinyaku Co., Ltd.	Phase 2	NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
2026-09-15	US	CORT	Corcept Therapeutics Incorporated	Phase 2	REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism
2026-09-15	US	CORT	Corcept Therapeutics Incorporated	Phase 2	REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism
2026-09-21	US	CRDL	Cardiol Therapeutics Inc.	Phase 3	CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
2026-09-25	US	VIR	Vir Biotechnology, Inc.	Phase 1	Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
2026-09-28	US	MLTX	MoonLake Immunotherapeutics	Phase 3	An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
2026-09-28	US	OCGN	Ocugen, Inc.	Phase 3	A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
2026-09-30	US	ALEC	Alector, Inc.	Phase 2	Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
2026-09-30	US	ATRA	Atara Biotherapeutics, Inc.	Phase 1	Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
2026-09-30	US	CERS	Cerus Corporation	Phase 2 – Withdrawn	Biotin-Acridine Red Cell Exchange Kinetics
2026-09-30	Ex-US	CHIZF	China Traditional Chinese Medicine Holdings Co. Limited	Phase 1	The Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastatic Adenocarcinoma
2026-09-30	US	CHRS	Coherus Oncology, Inc.	Phase 1	Study of CHS-114 in Participants With Advanced Solid Tumors
2026-09-30	US	MAJI	Marijuana Inc.	Phase 2	Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
2026-09-30	US	MJNA	Medical Marijuana, Inc.	Phase 2	Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
2026-09-30	US	QURE	uniQure N.V.	Phase 2	Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
2026-09-30	US	RPTX	Repare Therapeutics Inc.	Phase 2	A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
2026-09-30	Ex-US	SYMQY	SymBio Pharmaceuticals Limited	Phase 2	A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
2026-10-01	US	ABOS	Acumen Pharmaceuticals, Inc.	Phase 2	A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
2026-10-01	US	ADCT	ADC Therapeutics SA	Phase 2	Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
2026-10-01	US	AGEN	Agenus Inc.	Phase 2	Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
2026-10-01	Ex-US	ATGGF	Actinogen Medical Limited	Phase 3	Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
2026-10-01	US	BCRX	BioCryst Pharmaceuticals, Inc.	Phase 1	A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
2026-10-01	US	BHVN	Biohaven Ltd.	Phase 3	Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
2026-10-01	Ex-US	CASBF	CanSino Biologics Inc.	Phase 2	A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers
2026-10-01	Ex-US	CASBF	CanSino Biologics Inc.	Phase 1	Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
2026-10-01	US	CLDX	Celldex Therapeutics, Inc.	Phase 3	A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
2026-10-01	US	CLDX	Celldex Therapeutics, Inc.	Phase 3	A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
2026-10-01	US	COCP	Cocrystal Pharma, Inc.	Phase 2	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus
2026-10-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
2026-10-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
2026-10-01	US	EYPT	EyePoint, Inc.	Phase 3	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
2026-10-01	US	IDYA	IDEAYA Biosciences, Inc.	Phase 1	A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
2026-10-01	US	IMCR	Immunocore Holdings plc	Phase 2	Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
2026-10-01	Ex-US	INCPF	InnoCare Pharma Limited	Phase 2	Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
2026-10-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 2	E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
2026-10-01	US	IRON	Disc Medicine, Inc.	Phase 2	Study of DISC-0974-201 in Participants With IBD and Anemia
2026-10-01	US	ITRM	Iterum Therapeutics plc	Phase 1	Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents
2026-10-01	US	JANX	Janux Therapeutics, Inc.	Phase 1	Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
2026-10-01	US	JBIO	Jade Biosciences, Inc.	Phase 1	A Phase 1 Study of JADE101 in Healthy Participants
2026-10-01	US	KZIA	Kazia Therapeutics Limited	Phase 2	Genetic Testing in Guiding Treatment for Patients With Brain Metastases
2026-10-01	US	MIRM	Mirum Pharmaceuticals, Inc.	Phase 3	Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
2026-10-01	US	NTHI	NeOnc Technologies Holdings, Inc.	Phase 1	A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
2026-10-01	US	OGN	Organon & Co.	Phase 3	Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
2026-10-01	US	PHAR	Pharming Group N.V.	Phase 2	Leniolisib for Immune Dysregulation in CVID
2026-10-01	US	PHAR	Pharming Group N.V.	Phase 2	Leniolisib for Immune Dysregulation in CVID
2026-10-01	US	PHAT	Phathom Pharmaceuticals, Inc.	Phase 2	A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
2026-10-01	US	RGNX	REGENXBIO Inc.	Phase 3	Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
2026-10-01	US	RGNX	REGENXBIO Inc.	Phase 3	Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
2026-10-01	US	SNDX	Syndax Pharmaceuticals, Inc.	Phase 1	Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
2026-10-01	US	SRNE	Sorrento Therapeutics, Inc.	Phase 1	Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
2026-10-01	US	TENX	Tenax Therapeutics, Inc.	Phase 3	LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
2026-10-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 2	Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
2026-10-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 2	Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
2026-10-01	US	XENE	Xenon Pharmaceuticals Inc.	Phase 3	A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
2026-10-02	US	FTRE	Fortrea Holdings Inc.	Phase 1	AZD5305 hADME in Patients With Advanced Solid Malignancies
2026-10-02	US	PSTV	Plus Therapeutics, Inc.	Phase 1	Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
2026-10-09	US	TECX	Tectonic Therapeutic, Inc.	Phase 2	A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
2026-10-15	US	SLDB	Solid Biosciences Inc.	Phase 2	Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
2026-10-16	US	IOBT	IO Biotech, Inc.	Phase 2	Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
2026-10-24	US	PHAR	Pharming Group N.V.	PDUFA – CRL
2026-10-30	US	ADCT	ADC Therapeutics SA	Phase 1	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
2026-10-30	US	INBX	Inhibrx Biosciences, Inc.	Phase 2	Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
2026-10-30	US	INO	INOVIO Pharmaceuticals, Inc.	PDUFA
2026-10-30	US	MBX	MBX Biosciences, Inc.	Phase 1	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
2026-10-31	US	ADAG	Adagene Inc.	Phase 2	ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
2026-10-31	US	ANNX	Annexon, Inc.	Phase 3	A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
2026-10-31	US	IMMP	Immutep Limited	Phase 3	Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy
2026-10-31	US	JSPR	Jasper Therapeutics, Inc.	Phase 2	Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
2026-10-31	US	RCUS	Arcus Biosciences, Inc.	Phase 2	Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
2026-10-31	US	REPL	Replimune Group, Inc.	Phase 1	Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
2026-10-31	US	SNTI	Senti Biosciences, Inc.	Phase 1	Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
2026-10-31	US	SRPT	Sarepta Therapeutics, Inc.	Phase 3	A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
2026-10-31	US	SYRE	Spyre Therapeutics, Inc.	Phase 2	A Study of SPY072 in Rheumatic Disease
2026-10-31	US	TGTX	TG Therapeutics, Inc.	Phase 3	A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
2026-11-01	US	ACIU	AC Immune SA	Phase 1	[18F]ACI-19626 PET in TDP-43 Proteinopathies
2026-11-01	US	ANL	Adlai Nortye Ltd.	Phase 1	First in Human, Dose Escalation Study of AN4005
2026-11-01	US	APGE	Apogee Therapeutics, Inc.	Phase 2	A Study Evaluating APG777 in Atopic Dermatitis
2026-11-01	Ex-US	APTOF	Aptose Biosciences Inc.	Phase 2	Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
2026-11-01	US	ATOS	Atossa Therapeutics, Inc.	Phase 2	(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
2026-11-01	US	BHVN	Biohaven Ltd.	Phase 1	A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia
2026-11-01	US	BRNS	Barinthus Biotherapeutics plc	Phase 1	VTP-1000 in Adults With Celiac Disease
2026-11-01	US	BYSI	BeyondSpring Inc.	Phase 2	Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
2026-11-01	US	CGEM	Cullinan Therapeutics, Inc.	Phase 1	A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
2026-11-01	US	CGON	CG Oncology, Inc.	Phase 3	A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
2026-11-01	Ex-US	CHIZF	China Traditional Chinese Medicine Holdings Co. Limited	Phase 2	Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
2026-11-01	Ex-US	CHIZF	China Traditional Chinese Medicine Holdings Co. Limited	Phase 1	The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
2026-11-01	US	CRBP	Corbus Pharmaceuticals Holdings, Inc.	Phase 2	First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
2026-11-01	US	CRDF	Cardiff Oncology, Inc.	Phase 2	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
2026-11-01	US	DBVT	DBV Technologies S.A.	Phase 3	Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
2026-11-01	US	DRUG	Bright Minds Biosciences Inc.	Phase 2	A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.
2026-11-01	US	ELTX	Elicio Therapeutics, Inc.	Phase 2	A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
2026-11-01	US	HRMY	Harmony Biosciences Holdings, Inc.	Phase 3	An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
2026-11-01	US	IMUX	Immunic, Inc.	Phase 3	Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
2026-11-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 1	A Study of LN-144 in People With Metastatic Melanoma to the Brain
2026-11-01	US	KPRX	Kiora Pharmaceuticals, Inc.	Phase 2	Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
2026-11-01	Ex-US	MCUJF	Medicure Inc.	Phase 3	Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
2026-11-01	US	MGNX	MacroGenics, Inc.	Phase 1	A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
2026-11-01	US	MGNX	MacroGenics, Inc.	Phase 1	A Study of MGC028 in Participants With Advanced Solid Tumors
2026-11-01	US	NAMS	NewAmsterdam Pharma Company N.V.	Phase 3	Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
2026-11-01	US	RCUS	Arcus Biosciences, Inc.	Phase 1	A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
2026-11-01	US	SRRK	Scholar Rock Holding Corporation	Phase 3	Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
2026-11-01	US	STJO	St. Joseph, Inc.	Phase 2	Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
2026-11-01	US	TLX	Telix Pharmaceuticals Limited	Phase 1	PSMA PET Response Guided SabR in High Risk Pca
2026-11-01	US	TYRA	Tyra Biosciences, Inc.	Phase 2	Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
2026-11-01	US	VIR	Vir Biotechnology, Inc.	Phase 2	A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
2026-11-01	US	ZURA	Zura Bio Limited	Phase 2	Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
2026-11-18	US	SYRE	Spyre Therapeutics, Inc.	Phase 1	A Study of SPY003-207 in Healthy Volunteers
2026-11-20	US	SKYE	Skye Bioscience, Inc.	Phase 2	Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
2026-11-22	Ex-US	RVXCF	Resverlogix Corp.	Phase 2	A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
2026-11-24	Ex-US	CASBF	CanSino Biologics Inc.	Phase 2	Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
2026-11-25	Ex-US	INCPF	InnoCare Pharma Limited	Phase 3	ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
2026-11-30	US	AURA	Aura Biosciences, Inc.	Phase 2	Suprachoroidal Administration in Subjects With Metastases to the Choroid
2026-11-30	US	BIOA	BioAge Labs, Inc.	Phase 2	A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
2026-11-30	Ex-US	BVNRY	Bavarian Nordic A/S	Phase 2	Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
2026-11-30	US	IMCR	Immunocore Holdings plc	Phase 2	Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
2026-11-30	US	QURE	uniQure N.V.	Phase 2	AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
2026-11-30	US	REPL	Replimune Group, Inc.	Phase 1	Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
2026-11-30	US	RNAC	Cartesian Therapeutics, Inc.	Phase 3	Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
2026-12-01	US	ABUS	Arbutus Biopharma Corporation	Phase 2	Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
2026-12-01	US	ACLX	Arcellx, Inc.	Phase 2	Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
2026-12-01	US	ADCT	ADC Therapeutics SA	Phase 1	A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
2026-12-01	US	AGEN	Agenus Inc.	Phase 2	Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR – MSS CRC, and Other Metastatic GI Cancers
2026-12-01	US	AGEN	Agenus Inc.	Phase 2	Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
2026-12-01	US	ALDX	ALDEYRA THERAPEUTICS, INC.	Phase 3	A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
2026-12-01	US	ALMS	Alumis Inc.	Phase 2	Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
2026-12-01	US	ANRO	Alto Neuroscience, Inc.	Phase 2	Study of ALTO-300 in MDD
2026-12-01	US	ARDX	Ardelyx, Inc.	Phase 2	Tenapanor in Synucleinopathy-Related Constipation
2026-12-01	US	ATXS	Astria Therapeutics, Inc.	Phase 3	A Study of Navenibart in Participants With Hereditary Angioedema
2026-12-01	US	AVIR	Atea Pharmaceuticals, Inc.	Phase 3	C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
2026-12-01	US	BCDA	BioCardia, Inc.	Phase 2	Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells
2026-12-01	US	BEAM	Beam Therapeutics Inc.	Phase 2	A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
2026-12-01	US	BHVN	Biohaven Ltd.	Phase 3	A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
2026-12-01	US	BHVN	Biohaven Ltd.	Phase 2	Long-term Safety and Tolerability of BHV-7000
2026-12-01	Ex-US	BRIBF	Brii Biosciences Limited	Phase 2	Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
2026-12-01	US	BRTX	BioRestorative Therapies, Inc.	Phase 2	A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
2026-12-01	US	CGEM	Cullinan Therapeutics, Inc.	Phase 1	A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
2026-12-01	US	CMPX	Compass Therapeutics, Inc.	Phase 1	A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
2026-12-01	US	CNTA	Centessa Pharmaceuticals plc	Phase 2	A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
2026-12-01	US	CNTX	Context Therapeutics Inc.	Phase 1	CT-95 in Advanced Cancers Associated With Mesothelin Expression
2026-12-01	US	DCTH	Delcath Systems, Inc.	Phase 2	Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
2026-12-01	US	DMAC	DiaMedica Therapeutics Inc.	Phase 3	Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
2026-12-01	US	DNLI	Denali Therapeutics Inc.	Phase 2	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
2026-12-01	US	DSGN	Design Therapeutics, Inc.	Phase 2	A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
2026-12-01	US	EIKN	Eikon Therapeutics, Inc.	Phase 2	A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
2026-12-01	US	EPRX	Eupraxia Pharmaceuticals Inc.	Phase 2	A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
2026-12-01	US	GLSI	Greenwich LifeSciences, Inc.	Phase 3	Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
2026-12-01	US	GNLX	Genelux Corporation	Phase 2	Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
2026-12-01	US	GOSS	Gossamer Bio, Inc.	Phase 3	Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
2026-12-01	US	IMMX	Immix Biopharma, Inc.	Phase 2	Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
2026-12-01	US	IXHL	Incannex Healthcare Inc.	Phase 3	RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA
2026-12-01	US	KPTI	Karyopharm Therapeutics Inc.	Phase 2	Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2026-12-01	US	KPTI	Karyopharm Therapeutics Inc.	Phase 3	A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
2026-12-01	US	KZIA	Kazia Therapeutics Limited	Phase 1	GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
2026-12-01	US	KZIA	Kazia Therapeutics Limited	Phase 2	Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
2026-12-01	US	LXEO	Lexeo Therapeutics, Inc.	Phase 2	Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
2026-12-01	US	MDWD	MediWound Ltd.	Phase 3	A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
2026-12-01	US	MGTX	MeiraGTx Holdings plc	Phase 2	A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
2026-12-01	US	MNPR	Monopar Therapeutics Inc.	Phase 1	Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
2026-12-01	Ex-US	NPPNY	Nippon Shinyaku Co., Ltd.	Phase 2	Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
2026-12-01	US	NVCT	Nuvectis Pharma, Inc.	Phase 1	Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
2026-12-01	US	NXTC	NextCure, Inc.	Phase 1	A Phase 1 Study of LNCB74 in Advanced Solid Tumors
2026-12-01	US	OMER	Omeros Corporation	Phase 2	Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
2026-12-01	US	ORIC	ORIC Pharmaceuticals, Inc.	Phase 1	ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
2026-12-01	US	PBYI	Puma Biotechnology, Inc.	Phase 2	Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
2026-12-01	US	PMN	ProMIS Neurosciences, Inc.	Phase 1	PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
2026-12-01	US	PRAX	Praxis Precision Medicines, Inc.	Phase 3	A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
2026-12-01	US	RANI	Rani Therapeutics Holdings, Inc.	Phase 1	An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.
2026-12-01	US	RCUS	Arcus Biosciences, Inc.	Phase 2	A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
2026-12-01	US	RCUS	Arcus Biosciences, Inc.	Phase 2	Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
2026-12-01	US	RCUS	Arcus Biosciences, Inc.	Phase 2	Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
2026-12-01	US	RCUS	Arcus Biosciences, Inc.	Phase 1	A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants
2026-12-01	US	RGNX	REGENXBIO Inc.	Phase 3	Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
2026-12-01	US	SNDX	Syndax Pharmaceuticals, Inc.	Phase 2	A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
2026-12-01	US	SNDX	Syndax Pharmaceuticals, Inc.	Phase 2	A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
2026-12-01	Ex-US	TLTFF	Theralase Technologies Inc.	Phase 2	Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
2026-12-01	US	TVTX	Travere Therapeutics, Inc.	Phase 1	Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
2026-12-01	US	VIR	Vir Biotechnology, Inc.	Phase 2	Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
2026-12-01	US	VIR	Vir Biotechnology, Inc.	Phase 3	A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
2026-12-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 3	Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
2026-12-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 3	Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
2026-12-01	US	ZNTL	Zentalis Pharmaceuticals, Inc.	Phase 2	A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
2026-12-01	US	ZYME	Zymeworks Inc.	Phase 1	A Study of ZW191 in Participants With Solid Tumors
2026-12-02	US	XNCR	Xencor, Inc.	Phase 2	XmAb20717 in Advanced Biliary Tract Cancers
2026-12-03	US	VSTM	Verastem, Inc.	Phase 1	Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
2026-12-04	US	ARVN	Arvinas, Inc.	Phase 1	A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
2026-12-15	US	CRDF	Cardiff Oncology, Inc.	Phase 2	Onvansertib + Paclitaxel In TNBC
2026-12-15	Ex-US	GEDSF	Gedeon Richter PLC	Phase 3	Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
2026-12-22	US	ENSC	Ensysce Biosciences, Inc.	Phase 1	Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
2026-12-28	Ex-US	INCPF	InnoCare Pharma Limited	Phase 2	A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
2026-12-30	US	ARVN	Arvinas, Inc.	Phase 2	TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
2026-12-30	US	ARVN	Arvinas, Inc.	Phase 3	Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
2026-12-30	US	ARVN	Arvinas, Inc.	Phase 3	Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
2026-12-30	US	HOTH	Hoth Therapeutics, Inc.	Phase 2	Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
2026-12-30	US	IMCR	Immunocore Holdings plc	Phase 2	Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
2026-12-30	US	NTHI	NeOnc Technologies Holdings, Inc.	Phase 2	NEO100 and High-Grade Meningioma
2026-12-30	Ex-US	PSYGF	Psyence Group Inc.	Phase 2	Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
2026-12-30	US	SNDX	Syndax Pharmaceuticals, Inc.	Phase 2	A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
2026-12-30	US	SUPN	Supernus Pharmaceuticals, Inc.	Phase 2	BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
2026-12-30	US	TCRX	TScan Therapeutics, Inc.	Phase 1	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
2026-12-31	US	ACAD	ACADIA Pharmaceuticals Inc.	Phase 2	Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
2026-12-31	US	ADAG	Adagene Inc.	Phase 2	Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
2026-12-31	US	ADCT	ADC Therapeutics SA	Phase 1	Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
2026-12-31	US	ANNX	Annexon, Inc.	Phase 3	An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
2026-12-31	US	ARVN	Arvinas, Inc.	Phase 2	TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
2026-12-31	US	BCAX	Bicara Therapeutics Inc.	Phase 1	Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
2026-12-31	US	CATX	Perspective Therapeutics, Inc.	Phase 1	A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
2026-12-31	Ex-US	CHIZF	China Traditional Chinese Medicine Holdings Co. Limited	Phase 3	The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children
2026-12-31	Ex-US	CLRPF	Clarity Pharmaceuticals Ltd	Phase 3	64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
2026-12-31	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 1	A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
2026-12-31	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 1	CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
2026-12-31	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 1	CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
2026-12-31	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 1	Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
2026-12-31	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 1	The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
2026-12-31	US	ESLA	Estrella Immunopharma, Inc.	Phase 2	T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
2026-12-31	US	FBRX	Forte Biosciences, Inc.	Phase 1	A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
2026-12-31	US	FOLD	Amicus Therapeutics, Inc.	Phase 3	A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
2026-12-31	US	GOVX	GeoVax Labs, Inc.	Phase 2	SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
2026-12-31	US	INO	Inovio Pharmaceuticals, Inc.	Phase 2	INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
2026-12-31	Ex-US	JCRRF	JCR Pharmaceuticals Co., Ltd.	Phase 2	An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II
2026-12-31	Ex-US	MRCHF	H.U. Group Holdings, Inc.	Phase 1	Effect of Minimally Invasive Surgical Assisted by Robots on Intraventricular Hemorrhage
2026-12-31	US	PBYI	Puma Biotechnology, Inc.	Phase 1	Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
2026-12-31	US	PHIO	Phio Pharmaceuticals Corp.	Phase 1	Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
2026-12-31	US	STJO	St. Joseph, Inc.	Phase 1	Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
2026-12-31	US	SUPN	Supernus Pharmaceuticals, Inc.	Phase 2	Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
2026-12-31	US	VIR	Vir Biotechnology, Inc.	Phase 3	A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
2026-12-31	Ex-US	ZLDPF	Zealand Pharma A/S	Phase 3	Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
2027-01-01	US	ACAD	ACADIA Pharmaceuticals Inc.	Phase 2	Pimavanserin and Aggression and Social Cognition.
2027-01-01	US	AGEN	Agenus Inc.	Phase 1	Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
2027-01-01	Ex-US	ASPHF	Ascentage Pharma Group International	Phase 1	A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
2027-01-01	US	CALC	CalciMedica, Inc.	Phase 2	Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
2027-01-01	US	CGEM	Cullinan Therapeutics, Inc.	Phase 1	CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
2027-01-01	US	COYA	Coya Therapeutics, Inc.	Phase 2	Study of COYA 302 for the Treatment of ALS
2027-01-01	Ex-US	CSPHF	CStone Pharmaceuticals	Phase 2	A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
2027-01-01	US	ELDN	Eledon Pharmaceuticals, Inc.	Phase 2	Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
2027-01-01	US	ELVN	Enliven Therapeutics, Inc.	Phase 1	ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
2027-01-01	US	EWTX	Edgewise Therapeutics, Inc.	Phase 2	A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
2027-01-01	Ex-US	HOPHF	Hemogenyx Pharmaceuticals Plc	Phase 1	Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
2027-01-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 2	E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
2027-01-01	Ex-US	JBPHF	Jacobio Pharmaceuticals Group Co., Ltd.	Phase 2	JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
2027-01-01	US	KURA	Kura Oncology, Inc.	Phase 1	KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
2027-01-01	US	KURA	Kura Oncology, Inc.	Phase 1	Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
2027-01-01	US	KYTX	Kyverna Therapeutics, Inc.	Phase 2	Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis
2027-01-01	US	LRMR	Larimar Therapeutics, Inc.	Phase 2	An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
2027-01-01	US	NRIX	Nurix Therapeutics, Inc.	Phase 1	A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
2027-01-01	US	ORKA	Oruka Therapeutics, Inc.	Phase 1	ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose
2027-01-01	US	PYPD	PolyPid Ltd.	PDUFA
2027-01-01	US	RARE	Ultragenyx Pharmaceutical Inc.	Phase 3	Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
2027-01-01	US	RCUS	Arcus Biosciences, Inc.	Phase 2	A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
2027-01-01	US	REPL	Replimune Group, Inc.	Phase 2	Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
2027-01-01	US	REPL	Replimune Group, Inc.	Phase 2	Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
2027-01-01	US	SGMT	Sagimet Biosciences Inc.	Phase 1	Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
2027-01-01	US	XENE	Xenon Pharmaceuticals Inc.	Phase 3	An Open-Label Study of Azetukalner in Major Depressive Disorder
2027-01-01	US	ZVRA	Zevra Therapeutics, Inc.	Phase 2	Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
2027-01-03	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 1	a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
2027-01-03	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 1	A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
2027-01-03	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 1	A Study of CT0596 in Plasma Cell Leukemia
2027-01-04	Ex-US	PHCUF	Photocure ASA	Phase 3	Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
2027-01-07	US	IDYA	IDEAYA Biosciences, Inc.	Phase 1	Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
2027-01-08	US	FTRE	Fortrea Holdings Inc.	Phase 3	Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
2027-01-08	US	OCUL	Ocular Therapeutix, Inc.	Phase 3	Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
2027-01-13	US	FTRE	Fortrea Holdings Inc.	Phase 3	A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
2027-01-15	US	AZTR	Azitra, Inc.	Phase 2	A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
2027-01-15	US	IDYA	IDEAYA Biosciences, Inc.	Phase 3	IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
2027-01-15	US	MLTX	MoonLake Immunotherapeutics	Phase 3	Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
2027-01-15	US	XBIT	XBiotech Inc.	Phase 2	Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
2027-01-16	US	CRBP	Corbus Pharmaceuticals Holdings, Inc.	Phase 2	A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
2027-01-25	US	SGMT	Sagimet Biosciences Inc.	Phase 1	Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
2027-01-29	US	DVAX	Dynavax Technologies Corporation	Phase 2	Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
2027-01-29	US	IDYA	IDEAYA Biosciences, Inc.	Phase 2	Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
2027-01-31	US	APLM	Apollomics, Inc.	Phase 2	Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
2027-01-31	US	CELZ	Creative Medical Technology Holdings, Inc.	Phase 2	Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
2027-01-31	US	CUE	Cue Biopharma, Inc.	Phase 1	CUE-102 in Recurrent Glioblastoma
2027-01-31	Ex-US	SCNLF	Scancell Holdings plc	Phase 2	SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
2027-02-01	US	ABCL	AbCellera Biologics Inc.	Phase 2	Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
2027-02-01	US	AMLX	Amylyx Pharmaceuticals, Inc.	Phase 1	AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
2027-02-01	Ex-US	BVNRY	Bavarian Nordic A/S	Phase 2	A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
2027-02-01	US	CING	Cingulate Inc.	Phase 3 – Suspended	Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
2027-02-01	US	CING	Cingulate Inc.	Phase 3 – Suspended	Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
2027-02-01	US	DAWN	Day One Biopharmaceuticals, Inc.	Phase 2	A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
2027-02-01	US	DNLI	Denali Therapeutics Inc.	Phase 1	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
2027-02-01	US	ENLV	Enlivex Therapeutics Ltd.	Phase 2	Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
2027-02-01	US	FBRX	Forte Biosciences, Inc.	Phase 1	A Study Testing the Safety and Effects of FB102 in Healthy Volunteers
2027-02-01	US	GERN	Geron Corporation	Phase 1	A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
2027-02-01	US	GNLX	Genelux Corporation	Phase 2	Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
2027-02-01	US	IRON	Disc Medicine, Inc.	Phase 2	A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
2027-02-01	US	KOD	Kodiak Sciences Inc.	Phase 3	A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) – PINNACLE
2027-02-01	US	KPTI	Karyopharm Therapeutics Inc.	Phase 1	Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
2027-02-01	US	KYTX	Kyverna Therapeutics, Inc.	Phase 1	CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
2027-02-01	Ex-US	LBTSF	Almirall, S.A.	Phase 2	A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
2027-02-01	US	SEPN	Septerna, Inc.	Phase 1	A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants
2027-02-01	US	SNDX	Syndax Pharmaceuticals, Inc.	Phase 1	A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
2027-02-01	US	SXTP	60 Degrees Pharmaceuticals, Inc.	Phase 2	B-FREE Chronic Babesiosis Study
2027-02-01	US	TVRD	Tvardi Therapeutics, Inc.	Phase 2	A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
2027-02-01	US	XNCR	Xencor, Inc.	Phase 1	Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
2027-02-02	US	LNTH	Lantheus Holdings, Inc.	Phase 1	A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
2027-02-04	US	MLTX	MoonLake Immunotherapeutics	Phase 3	Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
2027-02-07	US	SRNE	Sorrento Therapeutics, Inc.	Phase 1	Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
2027-02-12	US	OCGN	Ocugen, Inc.	Phase 3	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
2027-02-15	Ex-US	CASBF	CanSino Biologics Inc.	Phase 3	A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
2027-02-17	US	NVCR	NovoCure Limited	Phase 1	A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis
2027-02-28	US	FBRX	Forte Biosciences, Inc.	Phase 2	Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
2027-02-28	US	INSP	Inspire Medical Systems, Inc.	Phase 3	Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea
2027-02-28	Ex-US	MRCHF	H.U. Group Holdings, Inc.	Phase 3	Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
2027-02-28	US	NTHI	NeOnc Technologies Holdings, Inc.	Phase 2	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
2027-03-01	Ex-US	ACHFF	Arch Biopartners Inc.	Phase 2	LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
2027-03-01	US	ACLX	Arcellx, Inc.	Phase 1	A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
2027-03-01	US	ADCT	ADC Therapeutics SA	Phase 2	Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
2027-03-01	US	AGIO	Agios Pharmaceuticals, Inc.	Phase 2	AG-120 in People With IDH1 Mutant Chondrosarcoma
2027-03-01	US	ALGS	Aligos Therapeutics, Inc.	Phase 2	A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
2027-03-01	US	ALLR	Allarity Therapeutics, Inc.	Phase 2	Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
2027-03-01	US	AURA	Aura Biosciences, Inc.	Phase 1	A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
2027-03-01	US	CGEN	Compugen Ltd.	Phase 2	A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
2027-03-01	US	CLDX	Celldex Therapeutics, Inc.	Phase 1	A Study of CDX-622 in Participants With Mild to Moderate Asthma
2027-03-01	US	DAWN	Day One Biopharmaceuticals, Inc.	Phase 2	Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
2027-03-01	US	DNLI	Denali Therapeutics Inc.	Phase 2	Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
2027-03-01	US	DNLI	Denali Therapeutics Inc.	Phase 2	Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
2027-03-01	US	EWTX	Edgewise Therapeutics, Inc.	Phase 2	Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
2027-03-01	US	FDMT	4D Molecular Therapeutics, Inc.	Phase 2	4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
2027-03-01	Ex-US	INCPF	InnoCare Pharma Limited	Phase 2	Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
2027-03-01	Ex-US	IUGNF	Imugene Limited	Phase 1	CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
2027-03-01	US	MNKD	MannKind Corporation	Phase 2	INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
2027-03-01	US	MNKD	MannKind Corporation	Phase 2	INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
2027-03-01	US	NUVB	Nuvation Bio Inc.	Phase 2	Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
2027-03-01	US	NVCT	Nuvectis Pharma, Inc.	Phase 1	A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
2027-03-01	US	OCGN	Ocugen, Inc.	Phase 2	Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
2027-03-01	US	OCUL	Ocular Therapeutix, Inc.	Phase 3	A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
2027-03-01	US	PEPG	PepGen Inc.	Phase 2	A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
2027-03-01	US	PMVP	PMV Pharmaceuticals, Inc.	Phase 1	A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
2027-03-01	US	PSTV	Plus Therapeutics, Inc.	Phase 1	Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
2027-03-01	US	STOK	Stoke Therapeutics, Inc.	Phase 3	A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
2027-03-01	US	SXTP	60 Degrees Pharmaceuticals, Inc.	Phase 2	Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
2027-03-01	US	THAR	Tharimmune, Inc.	Phase 2	TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis
2027-03-01	US	URGN	UroGen Pharma Ltd.	Phase 3	A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
2027-03-01	US	VSTM	Verastem, Inc.	Phase 2	A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
2027-03-02	US	SNDX	Syndax Pharmaceuticals, Inc.	Phase 1	Revumenib in Combination With 7+3 + Midostaurin in AML
2027-03-07	Ex-US	ASPHF	Ascentage Pharma Group International	Phase 2	Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
2027-03-08	Ex-US	ORYZF	Oryzon Genomics S.A.	Phase 1	Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
2027-03-10	US	FBRX	Forte Biosciences, Inc.	Phase 1	A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
2027-03-12	US	TSHA	Taysha Gene Therapies, Inc.	Phase 2	First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
2027-03-12	US	TVTX	Travere Therapeutics, Inc.	Phase 2	Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
2027-03-12	US	TVTX	Travere Therapeutics, Inc.	Phase 2	Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
2027-03-14	US	ZLAB	Zai Lab Limited	Phase 3	A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
2027-03-15	US	CLDX	Celldex Therapeutics, Inc.	Phase 2	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
2027-03-31	US	ALT	Altimmune, Inc.	Phase 2	RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
2027-03-31	Ex-US	ASPHF	Ascentage Pharma Group International	Phase 3	A Study of Olverembatinib in SDH-deficient GIST.
2027-03-31	US	CGON	CG Oncology, Inc.	Phase 2	Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
2027-03-31	US	CLDX	Celldex Therapeutics, Inc.	Phase 2	DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
2027-03-31	US	HURA	TuHURA Biosciences, Inc.	Phase 3	Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
2027-03-31	Ex-US	KSPHF	Kissei Pharmaceutical Co., Ltd.	Phase 3	Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
2027-03-31	US	LEGN	Legend Biotech Corporation	Phase 1	A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
2027-03-31	Ex-US	MSCLF	Satellos Bioscience Inc.	Phase 2	Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
2027-03-31	US	TNGX	Tango Therapeutics, Inc.	Phase 2	Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
2027-04-01	US	ABCL	AbCellera Biologics Inc.	Phase 1	A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
2027-04-01	US	ASRT	Assertio Holdings, Inc.	Phase 2	Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease
2027-04-01	US	CGTX	Cognition Therapeutics, Inc.	Phase 2	A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
2027-04-01	Ex-US	CHIZF	China Traditional Chinese Medicine Holdings Co. Limited	Phase 3	Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
2027-04-01	US	CLYM	Climb Bio Inc	Phase 1	A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
2027-04-01	US	HRMY	Harmony Biosciences Holdings, Inc.	Phase 3	A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
2027-04-01	US	KOD	Kodiak Sciences Inc.	Phase 3	A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) – PEAK
2027-04-01	US	KPTI	Karyopharm Therapeutics Inc.	Phase 2	Selinexor and Backbone Treatments of Multiple Myeloma Patients
2027-04-01	US	KYTX	Kyverna Therapeutics, Inc.	Phase 2	KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
2027-04-01	US	MIRM	Mirum Pharmaceuticals, Inc.	Phase 2	A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
2027-04-01	US	NKTX	Nkarta, Inc.	Phase 2	A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
2027-04-01	US	RAPT	RAPT Therapeutics, Inc.	Phase 2	Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
2027-04-01	US	RCUS	Arcus Biosciences, Inc.	Phase 2	Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
2027-04-01	US	TLSA	Tiziana Life Sciences Ltd	Phase 2	A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
2027-04-01	US	VSTM	Verastem, Inc.	Phase 2	A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
2027-04-01	US	XENE	Xenon Pharmaceuticals Inc.	Phase 3	A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
2027-04-15	US	CLDX	Celldex Therapeutics, Inc.	Phase 1	Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
2027-04-24	US	ZJYL	Jin Medical International Ltd.	Phase 2	Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）
2027-04-25	Ex-US	ALMRY	Almirall SA	Phase 3	A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
2027-04-25	Ex-US	LBTSF	Almirall, S.A.	Phase 3	A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
2027-04-25	US	PYXS	Pyxis Oncology, Inc.	Phase 1	A Study of PYX-201 in Advanced Solid Tumors
2027-04-26	US	TLX	Telix Pharmaceuticals Limited	Phase 1	Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
2027-04-30	US	IDYA	IDEAYA Biosciences, Inc.	Phase 2	(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
2027-04-30	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 2	LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
2027-04-30	US	NBTX	Nanobiotix S.A.	Phase 1	NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
2027-04-30	Ex-US	NPPNY	Nippon Shinyaku Co., Ltd.	Phase 2	Extension Study of NS-089/NCNP-02 in DMD
2027-04-30	US	RCUS	Arcus Biosciences, Inc.	Phase 2	Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
2027-04-30	US	RLAY	Relay Therapeutics, Inc.	Phase 1	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
2027-05-01	US	ADPT	Adaptive Biotechnologies Corporation	Phase 2	Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
2027-05-01	US	AGIO	Agios Pharmaceuticals, Inc.	Phase 2 – Withdrawn	A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy
2027-05-01	US	BOLT	Bolt Biotherapeutics, Inc.	Phase 2	A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
2027-05-01	US	CMPX	Compass Therapeutics, Inc.	Phase 2	CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
2027-05-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 1	A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
2027-05-01	US	JBIO	Jade Biosciences, Inc.	Phase 1	A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants
2027-05-01	US	MGNX	MacroGenics, Inc.	Phase 2 – Suspended	Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
2027-05-01	US	RCUS	Arcus Biosciences, Inc.	Phase 1	A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
2027-05-01	US	RCUS	Arcus Biosciences, Inc.	Phase 2	Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
2027-05-01	US	VSTM	Verastem, Inc.	Phase 2 – Suspended	A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
2027-05-01	US	VXRT	Vaxart, Inc.	Phase 2	A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
2027-05-01	US	VYGR	Voyager Therapeutics, Inc.	Phase 2	VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
2027-05-01	US	XENE	Xenon Pharmaceuticals Inc.	Phase 3	A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
2027-05-01	US	ZURA	Zura Bio Limited	Phase 2	Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
2027-05-05	US	FTRE	Fortrea Holdings Inc.	Phase 1	A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
2027-05-06	US	SLDB	Solid Biosciences Inc.	Phase 2	A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
2027-05-25	Ex-US	ALMRY	Almirall SA	Phase 2	A Study of LAD191 in Adults With Hidradenitis Suppurativa
2027-05-25	Ex-US	LBTSF	Almirall, S.A.	Phase 2	A Study of LAD191 in Adults With Hidradenitis Suppurativa
2027-05-26	US	FDMT	4D Molecular Therapeutics, Inc.	Phase 1	Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
2027-05-27	US	MBX	MBX Biosciences, Inc.	Phase 2	Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
2027-05-30	US	ACRV	Acrivon Therapeutics, Inc.	Phase 2	A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
2027-05-30	US	OLMA	Olema Pharmaceuticals, Inc.	Phase 1	Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
2027-05-30	US	ZLAB	Zai Lab Limited	Phase 1	A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
2027-05-31	US	DAWN	Day One Biopharmaceuticals, Inc.	Phase 2	A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
2027-05-31	Ex-US	LBTSF	Almirall, S.A.	Phase 1	A Study of LAD106 in Healthy Adult Participants
2027-05-31	US	RIGL	Rigel Pharmaceuticals, Inc.	Phase 2	Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults
2027-05-31	US	SRPT	Sarepta Therapeutics, Inc.	Phase 3	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
2027-06-01	US	AKBA	Akebia Therapeutics, Inc.	Phase 2	A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
2027-06-01	US	ALXO	ALX Oncology Holdings Inc.	Phase 1	A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
2027-06-01	US	APRE	Aprea Therapeutics, Inc.	Phase 1	Study of APR-1051 in Patients With Advanced Solid Tumors
2027-06-01	US	BLLN	BillionToOne, Inc.	Phase 1	Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
2027-06-01	US	BMEA	Biomea Fusion, Inc.	Phase 2	Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
2027-06-01	US	BMEA	Biomea Fusion, Inc.	Phase 2	Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
2027-06-01	Ex-US	CHIZF	China Traditional Chinese Medicine Holdings Co. Limited	Phase 3	EFG vs IVIG in TAMG
2027-06-01	US	CRVS	Corvus Pharmaceuticals, Inc.	Phase 2	Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
2027-06-01	US	DAWN	Day One Biopharmaceuticals, Inc.	Phase 3	DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
2027-06-01	US	DNLI	Denali Therapeutics Inc.	Phase 3	An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
2027-06-01	US	FDMT	4D Molecular Therapeutics, Inc.	Phase 2	4D-710 in Adult Patients With Cystic Fibrosis
2027-06-01	US	FDMT	4D Molecular Therapeutics, Inc.	Phase 3	4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
2027-06-01	US	HUMA	Humacyte, Inc.	Phase 3	To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
2027-06-01	Ex-US	IDRSF	Idorsia Ltd	Phase 2	A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo
2027-06-01	US	IMMP	Immutep Limited	Phase 3	Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
2027-06-01	US	INBX	Inhibrx Biosciences, Inc.	Phase 2	Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
2027-06-01	Ex-US	INCPF	InnoCare Pharma Limited	Phase 1	ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
2027-06-01	US	IRON	Disc Medicine, Inc.	Phase 1	A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
2027-06-01	Ex-US	IUGNF	Imugene Limited	Phase 1	Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
2027-06-01	Ex-US	KHTRF	Knight Therapeutics Inc.	Phase 2	Dose Escalation For INtraprostatic LEsions
2027-06-01	US	KPTI	Karyopharm Therapeutics Inc.	Phase 2	A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
2027-06-01	US	KYTX	Kyverna Therapeutics, Inc.	Phase 1	A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
2027-06-01	US	KYTX	Kyverna Therapeutics, Inc.	Phase 2	Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis
2027-06-01	US	LBRX	LB Pharmaceuticals Inc.	Phase 3	Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia (NOVA-2)
2027-06-01	US	MIST	Milestone Pharmaceuticals Inc.	Phase 2	The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
2027-06-01	US	NMRA	Neumora Therapeutics, Inc.	Phase 3	Study to Assess the Safety and Effectiveness of NMRA-335140-501
2027-06-01	US	ORKA	Oruka Therapeutics, Inc.	Phase 2	Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
2027-06-01	US	PHVS	Pharvaris N.V.	Phase 3	Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
2027-06-01	US	PHVS	Pharvaris N.V.	Phase 3	Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
2027-06-01	US	RIGL	Rigel Pharmaceuticals, Inc.	Phase 2	Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
2027-06-01	US	RXRX	Recursion Pharmaceuticals, Inc.	Phase 2	Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
2027-06-01	US	SLDB	Solid Biosciences Inc.	Phase 1	A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
2027-06-01	US	SNSE	Sensei Biotherapeutics, Inc.	Phase 2	A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
2027-06-01	Ex-US	SOLTF	Nxera Pharma Co., Ltd.	Phase 2	HTL0039732 in Participants With Advanced Solid Tumours
2027-06-01	US	SRNE	Sorrento Therapeutics, Inc.	Phase 2 – Suspended	Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
2027-06-01	US	SVRA	Savara Inc.	Phase 3	Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
2027-06-01	US	TARA	Protara Therapeutics, Inc.	Phase 3	Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
2027-06-01	US	TLSI	TriSalus Life Sciences, Inc.	Phase 1	Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
2027-06-01	US	TNGX	Tango Therapeutics, Inc.	Phase 2	Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
2027-06-01	US	VRCA	Verrica Pharmaceuticals Inc.	Phase 3	Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
2027-06-01	US	VSTM	Verastem, Inc.	Phase 2	A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
2027-06-01	US	VSTM	Verastem, Inc.	Phase 2	A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
2027-06-01	US	VSTM	Verastem, Inc.	Phase 2	A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
2027-06-01	US	ZYME	Zymeworks Inc.	Phase 3	Personalized Medicine for Advanced Biliary Cancer Patients
2027-06-03	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 1	Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
2027-06-09	US	IOBT	IO Biotech, Inc.	Phase 2	A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
2027-06-15	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 2	Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
2027-06-23	Ex-US	ALMRY	Almirall SA	Phase 2	A Study of LAD603 in Adults With Alopecia Areata
2027-06-23	Ex-US	LBTSF	Almirall, S.A.	Phase 2	A Study of LAD603 in Adults With Alopecia Areata
2027-06-25	US	APLS	Apellis Pharmaceuticals, Inc.	Phase 2	A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
2027-06-25	US	FTRE	Fortrea Holdings Inc.	Phase 3	Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
2027-06-25	Ex-US	INCPF	InnoCare Pharma Limited	Phase 1	Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
2027-06-30	US	ACRS	Aclaris Therapeutics, Inc.	Phase 1	MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
2027-06-30	Ex-US	CRTHF	CARsgen Therapeutics Holdings Limited	Phase 1	A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
2027-06-30	Ex-US	CSPHF	CStone Pharmaceuticals	Phase 1	A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
2027-06-30	US	IMNN	Imunon, Inc.	Phase 2	Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
2027-06-30	US	INDP	Indaptus Therapeutics, Inc.	Phase 2	Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
2027-06-30	US	LEGN	Legend Biotech Corporation	Phase 1	The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
2027-06-30	US	MIRM	Mirum Pharmaceuticals, Inc.	Phase 3	A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
2027-06-30	US	PBYI	Puma Biotechnology, Inc.	Phase 2	A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
2027-06-30	US	RIGL	Rigel Pharmaceuticals, Inc.	Phase 2	Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
2027-06-30	US	RLMD	Relmada Therapeutics, Inc.	Phase 3 – Withdrawn	A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
2027-07-01	US	ANL	Adlai Nortye Ltd.	Phase 1	An Initial Evaluation of AN8025 in Solid Tumors
2027-07-01	US	APLS	Apellis Pharmaceuticals, Inc.	Phase 3	An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
2027-07-01	US	ARTV	Artiva Biotherapeutics, Inc.	Phase 1	Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
2027-07-01	US	BHVN	Biohaven Ltd.	Phase 1	Study of BHV-1400 in IgA Nephropathy
2027-07-01	US	FOLD	Amicus Therapeutics, Inc.	Phase 3	A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
2027-07-01	US	JANX	Janux Therapeutics, Inc.	Phase 1	Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
2027-07-01	US	MESO	Mesoblast Limited	Phase 3	Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
2027-07-01	US	MGNX	MacroGenics, Inc.	Phase 2	A Study of Lorigerlimab in Participants With Advanced Solid Tumors
2027-07-01	US	NTLA	Intellia Therapeutics, Inc.	Phase 3	A Phase 3 Study of NTLA-2001 in ATTRv-PN
2027-07-01	Ex-US	PBIGF	Paradigm Biopharmaceuticals Limited	Phase 3	A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
2027-07-01	US	RCUS	Arcus Biosciences, Inc.	Phase 2	Domvanalimab and Zimberelimab in Advanced Liver Cancers
2027-07-01	US	SGMO	Sangamo Therapeutics, Inc.	Phase 2	Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
2027-07-01	US	TLX	Telix Pharmaceuticals Limited	Phase 3	Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
2027-07-01	US	VKTX	Viking Therapeutics, Inc.	Phase 3	VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
2027-07-01	US	VKTX	Viking Therapeutics, Inc.	Phase 3	VK2735 for Weight Management Phase 3
2027-07-01	US	ZVRA	Zevra Therapeutics, Inc.	Phase 1	An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA)
2027-07-30	US	ADAG	Adagene Inc.	Phase 2	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
2027-07-30	US	ONCY	Oncolytics Biotech Inc.	Phase 2	A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
2027-07-30	US	TPST	Tempest Therapeutics, Inc.	Phase 2	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
2027-07-31	US	BTAI	BioXcel Therapeutics, Inc.	Phase 1	Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
2027-07-31	US	KYNB	Kyntra Bio, Inc.	Phase 2	FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
2027-07-31	US	MAIA	MAIA Biotechnology, Inc.	Phase 3	A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
2027-07-31	US	TGTX	TG Therapeutics, Inc.	Phase 2	A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
2027-08-01	US	ACAD	ACADIA Pharmaceuticals Inc.	Phase 2	ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
2027-08-01	US	ADCT	ADC Therapeutics SA	Phase 2	Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
2027-08-01	US	ARTV	Artiva Biotherapeutics, Inc.	Phase 1	AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
2027-08-01	Ex-US	ASPHF	Ascentage Pharma Group International	Phase 3	A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
2027-08-01	US	BBOT	BridgeBio Oncology Therapeutics, Inc.	Phase 1	BBO-11818 in Adult Subjects With KRAS Mutant Cancer
2027-08-01	US	BHVN	Biohaven Ltd.	Phase 3	A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
2027-08-01	US	CLLS	Cellectis S.A.	Phase 2	Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
2027-08-01	US	CLYM	Climb Bio Inc	Phase 2	A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
2027-08-01	US	KPRX	Kiora Pharmaceuticals, Inc.	Phase 2	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
2027-08-01	US	NVCR	NovoCure Limited	Phase 1	A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
2027-08-01	US	RARE	Ultragenyx Pharmaceutical Inc.	Phase 3	Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
2027-08-01	US	RARE	Ultragenyx Pharmaceutical Inc.	Phase 3	A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
2027-08-01	US	SUPN	Supernus Pharmaceuticals, Inc.	Phase 2	RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
2027-08-01	US	TLX	Telix Pharmaceuticals Limited	Phase 2	CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
2027-08-01	US	TNYA	Tenaya Therapeutics, Inc.	Phase 2	Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
2027-08-01	US	TVTX	Travere Therapeutics, Inc.	Phase 3	A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
2027-08-01	US	VRCA	Verrica Pharmaceuticals Inc.	Phase 3	Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
2027-08-01	US	ZJYL	Jin Medical International Ltd.	Phase 2	Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
2027-08-01	US	ZLAB	Zai Lab Limited	Phase 2	A Study of ZL-1310 in Participants With Selected Solid Tumors
2027-08-10	US	LCTX	Lineage Cell Therapeutics, Inc.	Phase 1	A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
2027-08-16	US	VIR	Vir Biotechnology, Inc.	Phase 2	To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
2027-08-16	US	VSTM	Verastem, Inc.	Phase 2	A Study of Avutometinib and Defactinib in People With Thyroid Cancer
2027-08-27	US	PMVP	PMV Pharmaceuticals, Inc.	Phase 1	A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
2027-08-29	US	NVCR	NovoCure Limited	Phase 2	A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
2027-08-30	US	LNTH	Lantheus Holdings, Inc.	Phase 1	A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
2027-08-30	US	RADX	Radiopharm Theranostics Limited	Phase 1	A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
2027-08-31	US	CRDF	Cardiff Oncology, Inc.	Phase 2	Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
2027-08-31	US	IART	Integra LifeSciences Holdings Corporation	Phase 2	Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy
2027-08-31	US	MIRM	Mirum Pharmaceuticals, Inc.	Phase 3	Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
2027-08-31	US	RIGL	Rigel Pharmaceuticals, Inc.	Phase 2	A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
2027-08-31	US	TLX	Telix Pharmaceuticals Limited	Phase 3	Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
2027-09-01	US	AGEN	Agenus Inc.	Phase 2	A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
2027-09-01	US	BHVN	Biohaven Ltd.	Phase 1	Study of BHV-1300 in Graves' Disease
2027-09-01	US	CHRS	Coherus Oncology, Inc.	Phase 2	A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
2027-09-01	US	CLYM	Climb Bio Inc	Phase 2	A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
2027-09-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
2027-09-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
2027-09-01	US	CSTL	Castle Biosciences, Inc.	Phase 3	Evaluation of D-Fi for the Treatment of Wounds Due to DEB
2027-09-01	US	HUMA	Humacyte, Inc.	Phase 3	Humacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma
2027-09-01	US	IMTX	Immatics N.V.	Phase 2	IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
2027-09-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 2	A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
2027-09-01	US	KTTA	Pasithea Therapeutics Corp.	Phase 1	PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
2027-09-01	US	KYTX	Kyverna Therapeutics, Inc.	Phase 3	KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
2027-09-01	US	NEO	NeoGenomics, Inc.	Phase 2	Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
2027-09-01	US	RARE	Ultragenyx Pharmaceutical Inc.	Phase 3	Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
2027-09-01	US	RCUS	Arcus Biosciences, Inc.	Phase 1	Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
2027-09-01	US	RZLT	Rezolute, Inc.	Phase 3	A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
2027-09-01	US	TLSI	TriSalus Life Sciences, Inc.	Phase 1	Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
2027-09-01	US	UPB	Upstream Bio, Inc.	Phase 2	A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
2027-09-01	Ex-US	VACBF	Nykode Therapeutics AS	Phase 2	Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
2027-09-01	US	XFOR	X4 Pharmaceuticals, Inc.	Phase 3	A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
2027-09-01	US	ZYME	Zymeworks Inc.	Phase 1	A Study of ZW251 in Participants With Advanced Solid Tumors
2027-09-29	US	ADPT	Adaptive Biotechnologies Corporation	Phase 2	MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
2027-09-29	US	VIR	Vir Biotechnology, Inc.	Phase 1	Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
2027-09-30	US	CNTA	Centessa Pharmaceuticals plc	Phase 3	A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
2027-09-30	US	FATE	Fate Therapeutics, Inc.	Phase 1	A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
2027-09-30	US	IMCR	Immunocore Holdings plc	Phase 1	Study of IMC-P115C in Advanced PRAME-Positive Cancers
2027-09-30	US	IVA	Inventiva S.A.	Phase 3	A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With MASH and Fibrosis Stages F2 and F3 (NATiV3)
2027-09-30	US	LEGN	Legend Biotech Corporation	Phase 1	A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
2027-09-30	US	MAIA	MAIA Biotechnology, Inc.	Phase 2	THIO Sequenced With Cemiplimab in Advanced NSCLC
2027-09-30	US	RNTX	Rein Therapeutics Inc.	Phase 2	A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
2027-09-30	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 3	Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
2027-09-30	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 3	Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
2027-10-01	US	AGEN	Agenus Inc.	Phase 2	A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
2027-10-01	US	APVO	Aptevo Therapeutics Inc.	Phase 1	APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
2027-10-01	US	CERS	Cerus Corporation	Phase 2	Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs
2027-10-01	US	CLYM	Climb Bio Inc	Phase 2	A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
2027-10-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
2027-10-01	US	CORT	Corcept Therapeutics Incorporated	Phase 2	A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
2027-10-01	US	EVMN	Evommune, Inc.	Phase 2	Study of EVO756 in Adults With Migraine
2027-10-01	US	EYPT	EyePoint, Inc.	Phase 3	CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
2027-10-01	US	EYPT	EyePoint, Inc.	Phase 3	COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
2027-10-01	US	JBIO	Jade Biosciences, Inc.	Phase 1	A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis
2027-10-01	US	MIRM	Mirum Pharmaceuticals, Inc.	Phase 2	Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
2027-10-01	US	NVCR	NovoCure Limited	Phase 2	Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
2027-10-01	US	OGN	Organon & Co.	Phase 2	Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
2027-10-01	US	OPK	OPKO Health, Inc.	Phase 2	Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
2027-10-01	US	ORKA	Oruka Therapeutics, Inc.	Phase 2	Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
2027-10-16	US	IMCR	Immunocore Holdings plc	Phase 3	IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
2027-10-20	Ex-US	KNTPF	Kintor Pharmaceutical Limited	Phase 3	To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
2027-10-23	Ex-US	SYMQY	SymBio Pharmaceuticals Limited	Phase 2 – Suspended	A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
2027-10-26	Ex-US	GSGTF	GenSight Biologics S.A.	Phase 2	Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
2027-10-30	US	PBYI	Puma Biotechnology, Inc.	Phase 2	A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
2027-10-30	US	TFX	Teleflex Incorporated	Phase 1	Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies
2027-10-30	US	TLX	Telix Pharmaceuticals Limited	Phase 2	Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
2027-10-31	US	CUE	Cue Biopharma, Inc.	Phase 2	Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
2027-10-31	Ex-US	JCRRF	JCR Pharmaceuticals Co., Ltd.	Phase 3	A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
2027-10-31	US	LXRX	Lexicon Pharmaceuticals, Inc.	Phase 2	Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
2027-10-31	Ex-US	NURPF	Neuren Pharmaceuticals Limited	Phase 3	A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
2027-11-01	US	CHRS	Coherus Oncology, Inc.	Phase 2	A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
2027-11-01	US	CRIS	Curis, Inc.	Phase 2	A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
2027-11-01	US	CRVS	Corvus Pharmaceuticals, Inc.	Phase 3	Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
2027-11-01	US	DVAX	Dynavax Technologies Corporation	Phase 2	Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
2027-11-01	Ex-US	JBPHF	Jacobio Pharmaceuticals Group Co., Ltd.	Phase 2	JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
2027-11-01	Ex-US	KSPHF	Kissei Pharmaceutical Co., Ltd.	Phase 3	A Clinical Study of KLH-2109 in Patients With Endometriosis
2027-11-01	US	MPLT	MapLight Therapeutics, Inc.	Phase 2	ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
2027-11-01	US	NAMS	NewAmsterdam Pharma Company N.V.	Phase 3	A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
2027-11-01	US	REPL	Replimune Group, Inc.	Phase 2	Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
2027-11-01	US	REPL	Replimune Group, Inc.	Phase 2	Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
2027-11-01	US	SABS	SAB Biotherapeutics, Inc.	Phase 2	SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
2027-11-01	US	VERA	Vera Therapeutics, Inc.	Phase 2	Atacicept in Multiple Glomerular Diseases
2027-11-01	US	VERA	Vera Therapeutics, Inc.	Phase 2	Atacicept in Multiple Glomerular Diseases
2027-11-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 3	Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
2027-11-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 3	Randomized Withdrawal Study in Patients With Schizophrenia
2027-11-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 3	Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
2027-11-01	US	VNDA	Vanda Pharmaceuticals Inc.	Phase 3	Randomized Withdrawal Study in Patients With Schizophrenia
2027-11-15	US	AURA	Aura Biosciences, Inc.	Phase 3	A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
2027-11-19	US	LNTH	Lantheus Holdings, Inc.	Phase 2	Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
2027-11-19	US	LNTH	Lantheus Holdings, Inc.	Phase 2	Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
2027-11-22	US	CGEN	Compugen Ltd.	Phase 1	A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
2027-11-30	US	ARVN	Arvinas, Inc.	Phase 2	A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
2027-11-30	US	CTMX	CytomX Therapeutics, Inc.	Phase 1	First In Human Study of CX-2051 in Advanced Solid Tumors
2027-11-30	Ex-US	FGHQF	Frontage Holdings Corporation	Phase 2	SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
2027-11-30	US	MYGN	Myriad Genetics, Inc.	Phase 2	SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
2027-11-30	US	SRPT	Sarepta Therapeutics, Inc.	Phase 1	A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
2027-11-30	US	ZJYL	Jin Medical International Ltd.	Phase 3	Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC
2027-12-01	Ex-US	ABSCF	AB Science S.A.	Phase 3	Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
2027-12-01	US	ADAG	Adagene Inc.	Phase 2	A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
2027-12-01	US	AKTS	Aktis Oncology, Inc.	Phase 1	A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
2027-12-01	US	AKTS	Aktis Oncology, Inc.	Phase 1	A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
2027-12-01	US	ALLO	Allogene Therapeutics, Inc.	Phase 2	Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
2027-12-01	US	ALXO	ALX Oncology Holdings Inc.	Phase 2	ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
2027-12-01	US	ANTX	AN2 Therapeutics, Inc.	Phase 2	Epetraborole in Patients With Mycobacterium Abscessus Lung Disease
2027-12-01	US	ANVS	Annovis Bio, Inc.	Phase 3	A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
2027-12-01	Ex-US	ASPHF	Ascentage Pharma Group International	Phase 1	APG-2449 in Patients With Advanced Solid Tumors
2027-12-01	US	BCTX	BriaCell Therapeutics Corp.	Phase 3	Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
2027-12-01	US	CANF	Can-Fite BioPharma Ltd.	Phase 3	A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
2027-12-01	US	CRBU	Caribou Biosciences, Inc.	Phase 1	CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
2027-12-01	US	DAWN	Day One Biopharmaceuticals, Inc.	Phase 1	To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
2027-12-01	US	DNLI	Denali Therapeutics Inc.	Phase 3	A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
2027-12-01	US	ELVN	Enliven Therapeutics, Inc.	Phase 1	A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
2027-12-01	US	FOLD	Amicus Therapeutics, Inc.	Phase 3	A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
2027-12-01	US	GOSS	Gossamer Bio, Inc.	Phase 2	Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
2027-12-01	Ex-US	INCPF	InnoCare Pharma Limited	Phase 2	A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
2027-12-01	US	INTS	Intensity Therapeutics, Inc.	Phase 3	A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
2027-12-01	US	KURA	Kura Oncology, Inc.	Phase 1	A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
2027-12-01	US	LEGN	Legend Biotech Corporation	Phase 1	Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
2027-12-01	US	LEGN	Legend Biotech Corporation	Phase 1	DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
2027-12-01	Ex-US	MDGEF	Medigene AG	Phase 1	EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
2027-12-01	US	MPLT	MapLight Therapeutics, Inc.	Phase 2	A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
2027-12-01	US	NTLA	Intellia Therapeutics, Inc.	Phase 3	MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2027-12-01	US	OPK	OPKO Health, Inc.	Phase 2	Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants
2027-12-01	US	QURE	uniQure N.V.	Phase 2	Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
2027-12-01	US	RADX	Radiopharm Theranostics Limited	Phase 1	HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
2027-12-01	US	RADX	Radiopharm Theranostics Limited	Phase 2	177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
2027-12-01	US	RARE	Ultragenyx Pharmaceutical Inc.	Phase 2	Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
2027-12-01	US	RCUS	Arcus Biosciences, Inc.	Phase 2	Study With Various Immunotherapy Treatments in Participants With Lung Cancer
2027-12-01	US	REPL	Replimune Group, Inc.	Phase 2	Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
2027-12-01	US	REPL	Replimune Group, Inc.	Phase 2	Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
2027-12-01	US	RGNX	REGENXBIO Inc.	Phase 2	Phase 2 Trial of RGX-314 in Adults With Center Involved – Diabetic Macular Edema (CI – DME)
2027-12-01	US	RGNX	REGENXBIO Inc.	Phase 2	Phase 2 Trial of RGX-314 in Adults With Center Involved – Diabetic Macular Edema (CI – DME)
2027-12-01	US	RIGL	Rigel Pharmaceuticals, Inc.	Phase 1	Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
2027-12-01	US	RNAC	Cartesian Therapeutics, Inc.	Phase 2	Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
2027-12-01	US	RPTX	Repare Therapeutics Inc.	Phase 1	Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
2027-12-01	US	SANA	Sana Biotechnology, Inc.	Phase 1	Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
2027-12-01	US	STRO	Sutro Biopharma, Inc.	Phase 1	A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
2027-12-01	US	TGTX	TG Therapeutics, Inc.	Phase 3	Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
2027-12-01	US	TGTX	TG Therapeutics, Inc.	Phase 1	A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
2027-12-01	US	TLX	Telix Pharmaceuticals Limited	Phase 3	The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
2027-12-01	US	VSTM	Verastem, Inc.	Phase 2	A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
2027-12-01	US	WVE	Wave Life Sciences Ltd.	Phase 2	A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
2027-12-01	US	XNCR	Xencor, Inc.	Phase 1	Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
2027-12-01	US	ZJYL	Jin Medical International Ltd.	Phase 3	Mecobalamin in Promoting Recurrent Laryngeal Nerve Function Recovery After Thyroid Surgery
2027-12-06	US	PYXS	Pyxis Oncology, Inc.	Phase 2	Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
2027-12-15	Ex-US	ORPOF	OSE IMMUNOTHERAPEUTICS	Phase 3	Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
2027-12-15	US	SNDX	Syndax Pharmaceuticals, Inc.	Phase 2	A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
2027-12-25	Ex-US	INCPF	InnoCare Pharma Limited	Phase 2	Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
2027-12-27	US	MBRX	Moleculin Biotech, Inc.	Phase 2	WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
2027-12-28	US	ZLAB	Zai Lab Limited	Phase 1	A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
2027-12-30	US	BEAM	Beam Therapeutics Inc.	Phase 2	A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
2027-12-30	US	CGEM	Cullinan Therapeutics, Inc.	Phase 1	A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
2027-12-30	US	MDWD	MediWound Ltd.	Phase 2	Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers
2027-12-30	US	RLAY	Relay Therapeutics, Inc.	Phase 1	A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
2027-12-30	Ex-US	TRGNF	Transgene SA	Phase 2	A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
2027-12-31	US	ADAG	Adagene Inc.	Phase 2	Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
2027-12-31	Ex-US	ASPHF	Ascentage Pharma Group International	Phase 1	A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.
2027-12-31	US	CATX	Perspective Therapeutics, Inc.	Phase 2	MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
2027-12-31	US	CHRS	Coherus Oncology, Inc.	Phase 2	PDT For Induction Therapy For Head And Neck Cancer
2027-12-31	US	CLDX	Celldex Therapeutics, Inc.	Phase 1	NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
2027-12-31	US	KNSA	Kiniksa Pharmaceuticals International, plc	Phase 3	Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
2027-12-31	US	KNSA	Kiniksa Pharmaceuticals International, plc	Phase 2	Transition to KPL-387 Monotherapy Dosing & Administration Study
2027-12-31	US	KURA	Kura Oncology, Inc.	Phase 2	Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
2027-12-31	Ex-US	LYPHF	Luye Pharma Group Ltd.	Phase 3	Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
2027-12-31	Ex-US	LYPHF	Luye Pharma Group Ltd.	Phase 2	A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia
2027-12-31	US	NKTR	Nektar Therapeutics	Phase 2	REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
2027-12-31	US	NUVL	Nuvalent, Inc.	Phase 1	A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
2027-12-31	US	OLMA	Olema Pharmaceuticals, Inc.	Phase 1	Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
2027-12-31	US	SRPT	Sarepta Therapeutics, Inc.	Phase 1	A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) – Non-Ambulatory Cohort
2027-12-31	US	SUPN	Supernus Pharmaceuticals, Inc.	Phase 2	SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
2027-12-31	US	VSTM	Verastem, Inc.	Phase 2	VS-6766+Abema+Fulv in Met HR+/HER- BC
2028-01-01	US	ACAD	ACADIA Pharmaceuticals Inc.	Phase 3	ACP-204 in Adults With Alzheimer's Disease Psychosis
2028-01-01	US	ACIU	AC Immune SA	Phase 2	A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
2028-01-01	US	ARTV	Artiva Biotherapeutics, Inc.	Phase 2	AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
2028-01-01	US	BHVN	Biohaven Ltd.	Phase 3	Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
2028-01-01	US	BLRX	BioLineRx Ltd.	Phase 1	SCD Stem Cell Mobilization and Apheresis Using Motixafortide
2028-01-01	US	CELC	Celcuity Inc.	Phase 2	Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
2028-01-01	US	CHRS	Coherus Oncology, Inc.	Phase 1	A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
2028-01-01	US	CRMD	CorMedix Inc.	Phase 3	Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
2028-01-01	Ex-US	CSPHF	CStone Pharmaceuticals	Phase 1	A Phase I Study of CS5007 in Participants With Advanced Solid Tumors
2028-01-01	US	CYDY	CytoDyn Inc.	Phase 2	The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)
2028-01-01	US	ELVN	Enliven Therapeutics, Inc.	Phase 1	ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
2028-01-01	US	FATE	Fate Therapeutics, Inc.	Phase 1	FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
2028-01-01	US	IMTX	Immatics N.V.	Phase 3	SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
2028-01-01	Ex-US	JBPHF	Jacobio Pharmaceuticals Group Co., Ltd.	Phase 2	A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
2028-01-01	US	KPTI	Karyopharm Therapeutics Inc.	Phase 2	A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
2028-01-01	US	LXRX	Lexicon Pharmaceuticals, Inc.	Phase 2	Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
2028-01-01	US	NRIX	Nurix Therapeutics, Inc.	Phase 2	A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
2028-01-01	US	OGN	Organon & Co.	Phase 3	A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
2028-01-01	US	OPK	OPKO Health, Inc.	Phase 2	Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
2028-01-01	US	RXRX	Recursion Pharmaceuticals, Inc.	Phase 2	Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
2028-01-01	US	SRNE	Sorrento Therapeutics, Inc.	Phase 2 – Suspended	Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
2028-01-01	US	TYRA	Tyra Biosciences, Inc.	Phase 1	Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
2028-01-15	US	VSTM	Verastem, Inc.	Phase 2	Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
2028-01-17	US	AGIO	Agios Pharmaceuticals, Inc.	Phase 1	A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
2028-01-30	US	MNKD	MannKind Corporation	Phase 2	Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
2028-01-31	US	ANL	Adlai Nortye Ltd.	Phase 1	Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
2028-02-01	US	ACAD	ACADIA Pharmaceuticals Inc.	Phase 2	Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
2028-02-01	US	AGEN	Agenus Inc.	Phase 2	A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
2028-02-01	US	BEAM	Beam Therapeutics Inc.	Phase 2	BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
2028-02-01	US	BHVN	Biohaven Ltd.	Phase 2	A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
2028-02-01	US	CLRB	Cellectar Biosciences, Inc.	Phase 1	Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
2028-02-01	US	NXTC	NextCure, Inc.	Phase 1	A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
2028-02-01	US	TYRA	Tyra Biosciences, Inc.	Phase 2	Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
2028-02-03	US	RAPP	Rapport Therapeutics, Inc.	Phase 2	A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
2028-02-04	US	MLTX	MoonLake Immunotherapeutics	Phase 3	A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
2028-02-28	Ex-US	JCRRF	JCR Pharmaceuticals Co., Ltd.	Phase 3	An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects
2028-02-28	US	MRKR	Marker Therapeutics, Inc.	Phase 1	Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
2028-03-01	US	ARVN	Arvinas, Inc.	Phase 1	A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
2028-03-01	US	GNPX	Genprex, Inc.	Phase 2	Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
2028-03-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 3	Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
2028-03-01	Ex-US	NPPNY	Nippon Shinyaku Co., Ltd.	Phase 2	NS-050/NCNP-03 in Boys With DMD (Meteor50)
2028-03-15	US	CGEM	Cullinan Therapeutics, Inc.	Phase 1	A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
2028-03-21	US	SLDB	Solid Biosciences Inc.	Phase 1	A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
2028-03-26	US	KPTI	Karyopharm Therapeutics Inc.	Phase 2	Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
2028-03-31	US	GERN	Geron Corporation	Phase 1	A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
2028-03-31	US	PBYI	Puma Biotechnology, Inc.	Phase 2	A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
2028-03-31	US	REPL	Replimune Group, Inc.	Phase 1	RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
2028-04-01	US	ARQT	Arcutis Biotherapeutics, Inc.	Phase 1	Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
2028-04-01	Ex-US	IDRSF	Idorsia Ltd	Phase 2 – Suspended	Department of Defense PTSD Adaptive Platform Trial – Intervention C – Daridorexant
2028-04-01	US	RCKT	Rocket Pharmaceuticals, Inc.	Phase 2	A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
2028-04-01	US	RCUS	Arcus Biosciences, Inc.	Phase 3	Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
2028-04-01	US	UPB	Upstream Bio, Inc.	Phase 2	A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
2028-04-01	US	XNCR	Xencor, Inc.	Phase 2	Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
2028-04-20	US	CLDX	Celldex Therapeutics, Inc.	Phase 1	CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
2028-04-30	US	IPHA	Innate Pharma S.A.	Phase 2	Study of Lacutamab in Peripheral T-cell Lymphoma
2028-04-30	US	RGNX	REGENXBIO Inc.	Phase 3	RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
2028-04-30	US	RLAY	Relay Therapeutics, Inc.	Phase 3	Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
2028-04-30	US	VRCA	Verrica Pharmaceuticals Inc.	Phase 3	Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
2028-05-01	US	BEAM	Beam Therapeutics Inc.	Phase 2	A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
2028-05-01	Ex-US	IDRSF	Idorsia Ltd	Phase 2 – Suspended	Department of Defense PTSD Adaptive Platform Trial – Intervention A – Fluoxetine
2028-05-01	Ex-US	IDRSF	Idorsia Ltd	Phase 2	Department of Defense PTSD Adaptive Platform Trial – Intervention B – Vilazodone
2028-05-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 2	A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
2028-05-30	US	CHRS	Coherus Oncology, Inc.	Phase 1	A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
2028-05-31	US	CNTX	Context Therapeutics Inc.	Phase 1	A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
2028-05-31	US	ZNTL	Zentalis Pharmaceuticals, Inc.	Phase 3	A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
2028-06-01	US	IMRX	Immuneering Corporation	Phase 3	Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
2028-06-01	US	IRON	Disc Medicine, Inc.	Phase 3	HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
2028-06-01	Ex-US	LYPHF	Luye Pharma Group Ltd.	Phase 3	Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
2028-06-01	US	RXRX	Recursion Pharmaceuticals, Inc.	Phase 1	Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
2028-06-01	US	XENE	Xenon Pharmaceuticals Inc.	Phase 3	A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
2028-06-01	US	XNCR	Xencor, Inc.	Phase 1	A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
2028-06-13	US	MLTX	MoonLake Immunotherapeutics	Phase 3	A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
2028-06-30	US	GERN	Geron Corporation	Phase 3	A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
2028-06-30	Ex-US	JCRRF	JCR Pharmaceuticals Co., Ltd.	Phase 2	A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
2028-06-30	US	MGNX	MacroGenics, Inc.	Phase 2 – Suspended	Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
2028-06-30	US	TENX	Tenax Therapeutics, Inc.	Phase 3	LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
2028-06-30	US	ZNTL	Zentalis Pharmaceuticals, Inc.	Phase 1	A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
2028-07-01	Ex-US	IDRSF	Idorsia Ltd	Phase 2 – Suspended	Department of Defense PTSD Adaptive Platform Trial – Master Protocol
2028-07-01	US	TGTX	TG Therapeutics, Inc.	Phase 2	A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
2028-07-09	US	FTRE	Fortrea Holdings Inc.	Phase 3	Pediatric Patients Aged 1 to 6 Years With APDS
2028-07-09	US	PHAR	Pharming Group N.V.	Phase 3	Pediatric Patients Aged 1 to 6 Years With APDS
2028-07-09	US	PHAR	Pharming Group N.V.	Phase 3	Pediatric Patients Aged 1 to 6 Years With APDS
2028-07-16	US	MRKR	Marker Therapeutics, Inc.	Phase 1	MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
2028-07-31	US	CRIS	Curis, Inc.	Phase 1	CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
2028-08-01	US	DNLI	Denali Therapeutics Inc.	Phase 1	A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
2028-08-01	US	DNLI	Denali Therapeutics Inc.	Phase 2	Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
2028-08-01	US	HOWL	Werewolf Therapeutics, Inc.	Phase 2	A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
2028-08-28	US	SRPT	Sarepta Therapeutics, Inc.	Phase 1	A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
2028-09-01	US	BHVN	Biohaven Ltd.	Phase 3	A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
2028-09-01	US	MOLN	Molecular Partners AG	Phase 2	Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
2028-09-01	US	RCKT	Rocket Pharmaceuticals, Inc.	Phase 1	A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
2028-09-01	US	XBIT	XBiotech Inc.	Phase 2	Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
2028-09-15	US	BCAB	BioAtla, Inc.	Phase 1	Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
2028-10-01	US	NKTX	Nkarta, Inc.	Phase 2	A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
2028-10-01	US	XNCR	Xencor, Inc.	Phase 1	A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
2028-10-15	US	VSTM	Verastem, Inc.	Phase 3	A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
2028-10-16	US	KURA	Kura Oncology, Inc.	Phase 2	First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
2028-10-29	Ex-US	NURPF	Neuren Pharmaceuticals Limited	Phase 3	An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
2028-10-30	US	RXRX	Recursion Pharmaceuticals, Inc.	Phase 2	A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
2028-10-31	US	RIGL	Rigel Pharmaceuticals, Inc.	Phase 1	Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
2028-11-01	US	ALMS	Alumis Inc.	Phase 3	Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
2028-11-01	US	BBOT	BridgeBio Oncology Therapeutics, Inc.	Phase 1	Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
2028-11-02	US	TSHA	Taysha Gene Therapies, Inc.	Phase 2	Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
2028-11-30	Ex-US	ALMRY	Almirall SA	Phase 3	Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead
2028-11-30	Ex-US	LBTSF	Almirall, S.A.	Phase 3	Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead
2028-12-01	US	APLS	Apellis Pharmaceuticals, Inc.	Phase 2	A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
2028-12-01	US	INBX	Inhibrx Biosciences, Inc.	Phase 1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
2028-12-01	US	MYGN	Myriad Genetics, Inc.	Phase 1	SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
2028-12-01	US	NUVB	Nuvation Bio Inc.	Phase 3	SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
2028-12-01	US	OLMA	Olema Pharmaceuticals, Inc.	Phase 3	Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
2028-12-01	US	OTLC	Oncotelic Therapeutics, Inc.	Phase 2	OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
2028-12-01	US	VSTM	Verastem, Inc.	Phase 2	A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
2028-12-01	US	XNCR	Xencor, Inc.	Phase 1	Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
2028-12-31	Ex-US	LYPHF	Luye Pharma Group Ltd.	Phase 2	LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
2028-12-31	US	RARE	Ultragenyx Pharmaceutical Inc.	Phase 1	Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
2028-12-31	US	VCNX	Vaccinex, Inc.	Phase 2	Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
2029-01-01	US	JBIO	Jade Biosciences, Inc.	Phase 2	A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
2029-01-01	US	MIST	Milestone Pharmaceuticals Inc.	Phase 3	ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
2029-01-01	US	NUVB	Nuvation Bio Inc.	Phase 3	A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
2029-01-01	US	PEPG	PepGen Inc.	Phase 2	An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
2029-01-01	US	RCKT	Rocket Pharmaceuticals, Inc.	Phase 2 – Suspended	Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency
2029-01-01	US	RCKT	Rocket Pharmaceuticals, Inc.	Phase 2 – Suspended	Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency
2029-01-01	US	SLDB	Solid Biosciences Inc.	Phase 3	A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
2029-02-01	US	ACAD	ACADIA Pharmaceuticals Inc.	Phase 3	Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
2029-02-01	Ex-US	CASBF	CanSino Biologics Inc.	Phase 1	Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
2029-02-28	US	BOLD	Boundless Bio, Inc.	Phase 1	Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
2029-03-01	US	ABEO	Abeona Therapeutics Inc.	Phase 3	Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
2029-03-01	US	AGIO	Agios Pharmaceuticals, Inc.	Phase 3	A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia
2029-03-01	US	BHVN	Biohaven Ltd.	Phase 1	A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
2029-03-01	US	RARE	Ultragenyx Pharmaceutical Inc.	Phase 3	Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
2029-03-01	US	RARE	Ultragenyx Pharmaceutical Inc.	Phase 2	A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
2029-03-01	US	RCUS	Arcus Biosciences, Inc.	Phase 1	A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
2029-03-01	US	RXRX	Recursion Pharmaceuticals, Inc.	Phase 1	Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
2029-03-01	US	TENX	Tenax Therapeutics, Inc.	Phase 3	Long-Term Open-Label Extension Study of Oral Levosimendan
2029-03-02	US	AUPH	Aurinia Pharmaceuticals Inc.	Phase 2	Study of Aritinercept in Patients With Generalized Myasthenia Gravis
2029-03-02	US	SYRE	Spyre Therapeutics, Inc.	Phase 2	Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
2029-03-31	US	CELC	Celcuity Inc.	Phase 3	Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
2029-03-31	US	STOK	Stoke Therapeutics, Inc.	Phase 2	An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
2029-04-01	US	ACAD	ACADIA Pharmaceuticals Inc.	Phase 3	ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
2029-04-01	US	ACIU	AC Immune SA	Phase 2	A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
2029-05-01	US	ACAD	ACADIA Pharmaceuticals Inc.	Phase 3	OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
2029-05-01	US	DCTH	Delcath Systems, Inc.	Phase 2	Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
2029-05-01	Ex-US	IDRSF	Idorsia Ltd	Phase 2 – Suspended	Department of Defense PTSD Adaptive Platform Trial – Intervention D – SLS-002
2029-05-01	US	INBX	Inhibrx Biosciences, Inc.	Phase 3	INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
2029-05-01	US	MIRM	Mirum Pharmaceuticals, Inc.	Phase 3	A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
2029-06-01	US	APLS	Apellis Pharmaceuticals, Inc.	Phase 3 – Suspended	Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
2029-06-01	US	BYSI	BeyondSpring Inc.	Phase 3	Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
2029-06-01	US	RCKT	Rocket Pharmaceuticals, Inc.	Phase 1	A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
2029-06-01	US	XENE	Xenon Pharmaceuticals Inc.	Phase 3	An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
2029-06-30	US	TVRD	Tvardi Therapeutics, Inc.	Phase 1	Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
2029-07-01	Ex-US	INNMF	Amplia Therapeutics Limited	Phase 2	A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
2029-07-01	US	RAPP	Rapport Therapeutics, Inc.	Phase 3	Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
2029-07-01	US	RAPP	Rapport Therapeutics, Inc.	Phase 3	Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
2029-07-01	US	REPL	Replimune Group, Inc.	Phase 2	Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
2029-08-01	US	AGIO	Agios Pharmaceuticals, Inc.	Phase 3	A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
2029-08-01	Ex-US	IDRSF	Idorsia Ltd	Phase 3	A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
2029-08-01	US	MBRX	Moleculin Biotech, Inc.	Phase 3	L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
2029-08-01	US	VIR	Vir Biotechnology, Inc.	Phase 1	Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
2029-09-01	US	ANVS	Annovis Bio, Inc.	Phase 3	A Study of Buntanetap in Participants With PD
2029-09-01	US	MRKR	Marker Therapeutics, Inc.	Phase 1	Safety of MT-401-OTS in Patients With Relapsed AML or MDS
2029-09-01	US	RLMD	Relmada Therapeutics, Inc.	Phase 3	A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
2029-10-01	US	NRIX	Nurix Therapeutics, Inc.	Phase 3	Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
2029-10-01	Ex-US	PYCXF	PYC THERAPEUTICS LTD.	Phase 2	Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
2029-10-31	Ex-US	JCRRF	JCR Pharmaceuticals Co., Ltd.	Phase 2	Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA
2029-12-01	Ex-US	CSPHF	CStone Pharmaceuticals	Phase 3	Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
2029-12-01	Ex-US	ORPOF	OSE IMMUNOTHERAPEUTICS	Phase 2	Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
2029-12-01	US	PROK	ProKidney Corp.	Phase 3	Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
2029-12-31	US	PBYI	Puma Biotechnology, Inc.	Phase 2 – Suspended	Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
2030-01-01	US	CNTX	Context Therapeutics Inc.	Phase 1	A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
2030-01-01	US	RARE	Ultragenyx Pharmaceutical Inc.	Phase 2	A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
2030-01-01	US	TGTX	TG Therapeutics, Inc.	Phase 3	Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
2030-01-01	US	TYRA	Tyra Biosciences, Inc.	Phase 2	A Study of TYRA-300 in Children With Achondroplasia: BEACH301
2030-02-01	US	VCEL	Vericel Corporation	Phase 3	A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
2030-03-31	Ex-US	JCRRF	JCR Pharmaceuticals Co., Ltd.	Phase 3	An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
2030-04-01	US	KURA	Kura Oncology, Inc.	Phase 1	A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
2030-04-30	Ex-US	JCRRF	JCR Pharmaceuticals Co., Ltd.	Phase 2	An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
2030-05-01	US	CASI	CASI Pharmaceuticals, Inc.	Phase 2	A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).
2030-05-01	US	ORKA	Oruka Therapeutics, Inc.	Phase 2	An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
2030-06-16	US	CGON	CG Oncology, Inc.	Phase 3	Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
2030-07-01	US	VCEL	Vericel Corporation	Phase 3	A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
2030-08-01	US	OCUL	Ocular Therapeutix, Inc.	Phase 3	Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
2030-08-01	US	TVTX	Travere Therapeutics, Inc.	Phase 3	A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
2030-08-01	US	TVTX	Travere Therapeutics, Inc.	Phase 3	A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
2030-08-30	US	NUVB	Nuvation Bio Inc.	Phase 3	Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
2030-09-01	Ex-US	KSPHF	Kissei Pharmaceutical Co., Ltd.	Phase 2	A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia
2030-10-01	US	TYRA	Tyra Biosciences, Inc.	Phase 2	Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
2030-11-30	US	RCUS	Arcus Biosciences, Inc.	Phase 3	Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2030-12-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 2	Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
2031-02-01	US	DNLI	Denali Therapeutics Inc.	Phase 2	A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
2031-02-01	US	EWTX	Edgewise Therapeutics, Inc.	Phase 2	Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
2031-03-01	US	ATXS	Astria Therapeutics, Inc.	Phase 2	A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
2031-04-01	US	BBOT	BridgeBio Oncology Therapeutics, Inc.	Phase 1	Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
2031-05-21	US	VERA	Vera Therapeutics, Inc.	Phase 2	A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
2031-06-01	US	ATXS	Astria Therapeutics, Inc.	Phase 3	A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
2031-06-01	US	TSHA	Taysha Gene Therapies, Inc.	Phase 3	Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
2031-06-01	US	TSHA	Taysha Gene Therapies, Inc.	Phase 3	A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
2031-07-01	US	RLAY	Relay Therapeutics, Inc.	Phase 2	A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
2031-07-31	US	AGEN	Agenus Inc.	Phase 2	Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
2031-09-30	Ex-US	ASPHF	Ascentage Pharma Group International	Phase 2	Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
2031-10-22	US	CADL	Candel Therapeutics, Inc.	Phase 3	Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
2031-11-01	US	KURA	Kura Oncology, Inc.	Phase 3	Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
2031-11-01	US	VIR	Vir Biotechnology, Inc.	Phase 2	SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
2032-05-31	US	TGTX	TG Therapeutics, Inc.	Phase 3	An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
2032-06-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 2	A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
2032-12-01	US	IOVA	Iovance Biotherapeutics, Inc.	Phase 2	A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
2033-04-01	US	XENE	Xenon Pharmaceuticals Inc.	Phase 3	An Open-label Study of XEN1101 in Epilepsy
2033-05-01	US	NRIX	Nurix Therapeutics, Inc.	Phase 2	Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

FontiSources

ClinicalTrials.gov
Medicine in revisione EMAMedicines under EMA review
Run Up Biotech EuropaRun Up Biotech Europa

Avviso educativo e legale.Educational and legal notice. Merlintrader pubblica contenuti informativi ed educativi indipendenti. Nulla in questa pagina costituisce consulenza in materia di investimenti, consulenza finanziaria personalizzata, ricerca regolamentata, una raccomandazione, un’offerta o una sollecitazione all’acquisto o alla vendita di titoli, in linea con le indicazioni CONSOB (Italia) e SEC (USA). I titoli biotech e small-cap possono essere altamente volatili, illiquidi ed esposti a rischi clinici, regolatori, produttivi, di finanziamento e diluizione, inclusa la perdita parziale o totale. Le date dei trial sono stime che possono cambiare; verifica sempre su ClinicalTrials.gov e sulle fonti aziendali ufficiali.Merlintrader publishes independent informational and educational content. Nothing on this page constitutes investment advice, personalized financial advice, regulated research, a recommendation, an offer or a solicitation to buy or sell securities, consistent with CONSOB (Italy) and SEC (US) guidance. Biotech and small-cap securities can be highly volatile and illiquid. Trial dates are estimates that may change; always verify on ClinicalTrials.gov and official company sources.